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ABSTRACT

AGE-RELATED HOST FACTORS REGULATE
LUNG CANCER PROGRESSION

John Caleb Greenwell
November 14th, 2017

Cancer is largely a disease of the elderly. In the United States alone, 87% of all
cancers in 2017 will be diagnosed in individuals aged 50 years or older. Among
them, lung cancer is the deadliest, accounting for 1 in 4 cancer deaths. The 5-year
survival rate is below 20%, a number which has not changed substantially over the
past several decades. This underscores a desperate need for new strategies in
prevention, early detection and treatment of this deadly disease. While tobacco
use is unquestionably the number one risk factor for the development of lung
cancer, the majority of diagnoses occur in individuals with preexisting lung
conditions such as chronic obstructive pulmonary disease and idiopathic
pulmonary fibrosis, characterized by inflammation and remodeling of the
extracellular matrix. Fibronectin is one matrix protein upregulated in these settings.
Fibronectin EDA is a splice variant of fibronectin that is increased with aging and
has been shown to be a vascular marker for solid tumors and metastases.
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Moreover, immunization against fibronectin EDA decreases tumor burden and
lung metastases in the MMTV-PyMT transgenic model of metastatic mammary
carcinoma.
In this dissertation, I explore how age-related host factors regulate lung
progression. More specifically, I examine how tissue remodeling and aging act in
concert, through increased levels of fibronectin EDA, to render the host susceptible
to lung cancer progression. This and other work is described in 5 chapters: 1)
background and introduction; 2) the role of aging and tissue remodeling in lung
cancer; 3) the role of fibroblasts in lung cancer; 4) the role of sex and redox in lung
cancer; and 5) summary and discussion. The work described here suggests that
age-dependent host factors influence lung cancer progression. Importantly, lung
inflammation/tissue remodeling augments pulmonary metastasis in the aging lung,
but not in young lungs, through mechanisms involving fibronectin EDA, which
perhaps provides a scaffold for tumor cell migration/organization and proliferation.
This points to an interplay between lung aging and inflammation/remodeling in lung
tumor progression and describes a previously unknown role of fibronectin EDA in
lung cancer in the setting of lung injury and aging. Sex also appears to be
important, while oxidative stress may play a minor role. Finally, we show that
fibroblasts produce factors capable of influencing cancer progression.
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CHAPTER I

BACKGROUND AND INTRODUCTION

1.1 Epidemiology of Lung Cancer
Lung cancer is the leading cause of cancer death in men and women in the
Unites States (US). It is largely preventable, as most cases are due to tobacco
use. In 2017, there will be over an estimated 220,000 new cases of lung cancer,
which accounts for 14% of all cancer diagnoses [1]. Of those diagnosed, there will
be over an estimated 155,000 deaths, which is more than the next 3 major types
of cancer (colon, prostate, and breast) combined. Lung cancer is thus responsible
for more than one-quarter (27%) of all cancer deaths [2]. Due to the large number
of individuals affected by lung cancer, the national cost of lung cancer care in the
US in 2010 was estimated to be $12.12 billion, a significant burden on the
economy. Lung cancer was also found to be the condition with the highest cost in
the last year of life phase of care [3]. These data justify further research and efforts
in this area.
Lung cancer is diagnosed primarily in the elderly population. Cancer in
general is well known to be a disease of the aged. In the US alone, 87% of all
cancers in 2017 will be diagnosed in individuals 50 years or older. For lung cancer,
two-thirds of all new cases will be diagnosed in those older than 65 years, while
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the number of deaths from lung cancer in those under 20 years of age is expected
to be 0% [1].
The number one risk factor for the development of lung cancer is
unquestionably tobacco exposure. This was first reported in 1964, when Luther
Terry, the ninth Surgeon General of the United States, released his now famous
report titled, “Smoking and Health: Report of the Advisory Committee to the
Surgeon General of the United States,” which concluded that bronchitis and lung
cancer were causally related to cigarette smoking. Of all lung cancer deaths, 80%
are caused by smoking. This fact is strengthened by the striking geographic
variation in lung cancer deaths by state, where patterns of mortality cluster in areas
with the highest prevalence of smoking. Kentucky leads the nation in individuals
who smoke, while Utah contains the fewest smokers. Not surprisingly, the number
of lung cancer deaths in those states in 2017 is estimated to be 3560 compared to
460, respectively [1]. While the carcinogenic mechanisms of tobacco use are not
completely understood, research over the past 5 decades has revealed that we do
indeed know a great deal about how tobacco use causes lung cancer and that
there is certainly not a single mechanism, but several, responsible for tobacco
carcinogenesis. There have been over 8000 compounds identified in tobacco and
tobacco smoke [4]. Among them, the International Agency for Research on Cancer
has classified over 70 carcinogens capable of causing cancer in laboratory animals
and humans [5]. These carcinogens include the polycyclic aromatic hydrocarbons
(PAHs) and the tobacco specific nitrosamines (TSNAs). Many require metabolic
activation that then leads to the formation of DNA adducts by covalent binding. For
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example, benzo[a]pyrene diol epoxide has been shown to bind to select regions of
the p53 gene [6]. Overtime, DNA repair mechanisms fail, or are evaded, and due
to the cumulative nature of these adducts, permanent mutations are formed. If
these mutations occur in vital genes, oncogenes (e.g. KRAS) could be activated
and tumor suppressor genes (e.g. p53 and Rb) could be deactivated leading to the
development of cancer. While the contribution of such mutations in the
development of cancer cannot be overstated, mutations alone are not sufficient to
cause tumor growth. It has been shown that simultaneous expression of oncogenic
KRAS and knockdown of p53 was insufficient to confer a complete malignant
phenotype in human bronchial epithelial cells [7].
While lung cancer is often viewed solely as a smoker’s disease, not all lung
cancers occur in individuals who smoke [8]. This is an important fact to take note
of because lung cancers that develop in those who have never smoked differ
considerably from lung cancers in smokers. Significant differences in histologic
subtypes have been identified, with adenocarcinoma prevailing in never smokers
[9]. Exposure to radon gas, which can be trapped in residential homes, has been
proposed as the second leading cause of lung cancer after cigarette smoking
[10,11]. However, others have argued that studies showing an association
between radon exposure and lung cancer relied on a linear-no-threshold
hypothesis-based, risk assessment paradigm that has recently been invalidated.
Instead, using a hormetic relative risk model, radon exposure was shown to
actually protect against lung cancer [12]. Regardless, these studies establish the
point that a large number of individuals who develop lung cancer are never-
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smokers, and the proportion of individuals who develop lung cancer that have
never smoked is going to continually increase as smoking cessation efforts
continue, and thus research in this area must continue [13].
The overall incidence of lung cancer has been declining, but this is due
largely to smoking cessation efforts. For men, the incidence rate has been
declining since the mid 1980s, while for women, the rate did not start declining until
the early 2000s [2]. From 1990 to 2011, lung cancer death rates dropped by 36%
for men and 11% for women from 2002 to 2011 [14]. This decrease in death rates
matched a drop in the number of individuals smoking that began decades earlier.
In fact, it has been estimated that the Surgeon General’s report in 1964 resulted in
8 million fewer smoking-related deaths, with one-third of those being due to cancer.
This was associated with a decline in adult smoking rates from 43% (1965) to 18%
today [15]. Although this decline in smoking rates is to be celebrated, tobacco use
remains a major problem in the US and worldwide. Every day, it is estimated that
3200 youth smoke a cigarette for the first time, and 2100 youth and occasional
smokers progress to become daily smokers [15]. There also appears to be a high
-risk population of women born after 1950 in several Southern and Midwestern
states [16]. Thus, continued efforts in raising awareness of the health hazards of
tobacco use and additional interventions must be pursued in all areas of influence.
Unfortunately, the decline in the number of cigarette smokers in the US has
been met by an increase in the number of electronic cigarette (e-cig) users. E-cigs
are battery-powered devices that use heat to convert liquid nicotine and various
flavorings into an inhalable vapor. E-cigs were invented in 2003 and introduced
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into the market the following year as a “safe alternative” to cigarette smoking. Since
then, the number of e-cig users has grown at an alarming pace, especially among
the nation’s youth. Roughly 16% of current cigarette smokers and 22% of recent
former smokers currently use e-cigs on a regular basis [17]. E-cig sales in the US
are estimated to reach $10 billion in 2017, and are expected to surpass the sale of
standard cigarettes by 2023 [18]. While e-cigs are marketed as safer alternatives
to conventional cigarettes, numerous studies have shown that e-cigs contain
carcinogens found in cigarettes, as well as several metals and silicate particles
[19,20]. Long-term term studies evaluating the harmful effects of e-cigs and the
ability of e-cig use to cause or promote lung cancer have not been investigated.
However, due to their similar composition to conventional cigarettes (nicotine and
carcinogens), the drastic increase of e-cig use is a matter of great concern, and
additional studies are warranted in this area.

1.2 Diagnosis, Management, and Treatment of Lung Cancer
There are currently 2 major recognized types of lung cancer: small-cell lung
cancer (SCLC) and non-small-cell lung cancer (NSCLC), which is further divided
into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [21].
SCLC is highly aggressive, exhibits neuroendocrine characteristics, and accounts
for 15% of lung cancers. Of the remaining 85% of lung cancers, the vast majority
are NSCLC, with adenocarcinoma being the most common, followed by squamous
cell carcinoma, and lastly large cell carcinoma [14]. While smoking is associated
with every type of lung cancer, the association is strongest for SCLC and
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squamous cell carcinoma. In never smokers, adenocarcinoma is the most the
common type identified [9,22].
Symptoms of lung cancer include persistent cough, coughing up blood,
shortness of breath, wheezing, hoarseness, weight loss, chest pain, lethargy, and
others. A diagnosis is made using one or several of the following methods:
physical exam, chest x-ray, CT scan, PET scan, MRI, bone scan, sputum cytology,
bronchoscopy, or fine-needle aspiration biopsy of the lung. Once a diagnosis has
been made, oncologists use the principles set forth by the American Joint
Committee on Cancer for lung cancer staging. There are currently 4 recognized
stages of lung cancer, staged 1 - 4, with stages 1, 2 and 3 being further divided
into A and B subtypes [23]. Proper staging is of the utmost importance for the
determination of the appropriate treatment regimen. For example, surgical
resection is beneficial for patients with stages 1-2, while those with stages 3-4
rarely benefit from surgery [24]. Other treatment options include chemotherapy
alone or in combination with radiation.
Despite the steady increase in survival rates for most cancers, the current
relative 5-year survival rate for lung cancer is 18% and that number has only
increased slowly over the past several decades [2]. The survival rate decreases to
4% if distant metastases are present, which is a devastating reality because over
50% of all diagnoses are in this category [14]. This is one of the main reasons for
the low survival rate, largely due to the lack of symptoms until that time. This
underscores the need for early detection in lung cancer. It has been argued that
progress is being made in this area through recent developments in screening with
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spiral computed topography, which has been shown to decrease lung cancer
deaths in those who have a history of heavy smoking [25,26]. These reports,
however, as some have warned, must be taken with caution, as they introduce
lead time bias in survival rates [27]. Thus, age-adjusted mortality rates and not
survival rates might be a better measure of lung cancer incidence.

1.3 Aging
Aging is natural process of life that is unavoidable. It is largely due to the
progressive accumulation of damage in macromolecules that is marked by a
decline in the function of cells, tissues and ultimately organs. This decline in
physiological integrity renders organisms vulnerable to cancer, cardiovascular
disease, diabetes, and neurodegenerative diseases, among others.
Population aging, a process defined as an increase in the proportion of older
people and a decrease in the number of younger people, is becoming a major
problem in the US and worldwide. For example, in 1950 only 8% of the world’s
population was over the age of 60. That number grew to 11.2% by 2011, and is
projected to reach 22% by 2050. In contrast, the number of individuals under the
age of 15 is projected to decrease from 26.6% to 20% in 2050 [28]. The cause of
population aging is two-fold: one is a decrease in fertility rates, and two, increased
life expectancies. In the US, the fertility rate, defined as births per 1000 women, is
now the lowest it has ever been since such records started being kept more than
a century ago [29]. Increases in life expectancy in the past have mainly been due
to decreases in child mortality rates. Presently, however, increased life expectancy
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is due to decreases in mortality in the elderly. As the population continues to age,
the prevalence of chronic diseases, known as noncommunicable diseases (NCDs)
will continue to increase. In the US, 65% of health care costs are due to individuals
with at least one NCD [30]. This will become a major threat to our economy, as the
high health costs associated with NCDs will need to be sustained by a shrinking
working-age population.
While worldwide deaths from most NCDs (cancer and cardiovascular
diseases) are continuing to decline, those from chronic obstructive pulmonary
disease (COPD) are not and some estimate that they are growing. In fact, diseases
of the respiratory system are among the major contributors of the worldwide
burden of disease. For example, there are over 1 billion people globally who suffer
from chronic respiratory diseases such as asthma (300 million) and COPD (210
million) [31], with COPD expected to become the third leading cause of death by
2030 [32]. These respiratory diseases are disproportionately observed in the
elderly population [33,34], and may actually be underrepresented [35].
The association between aging and an increased susceptibility to
respiratory diseases has also been noted in several rodent models. For example,
old animals were shown to be more susceptible to bleomycin-induced pulmonary
fibrosis, and morphologic and functional changes due to chronic cigarette smoke
inhalation [36,37]. Old animals were also more susceptible to lung injury in the
setting of mechanical ventilation [38].
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1.4 Lung Tissue Remodeling
As previously mentioned, historically, lung cancer was thought to be caused
directly by mutations in the genome initiated by tobacco carcinogens. However,
numerous studies have shown that COPD and fibrotic diseases such as asbestosis
and idiopathic pulmonary fibrosis (IPF), characterized by inflammation and lung
tissue remodeling, are also risk factors for the development of cancer. For
example, as early as 1935, through autopsy studies, Gloyne identified cases of
squamous cell carcinoma in individuals with asbestosis [39]. Several decades
later, Haddad & Massaro, again through autopsy studies, found lung cancer
lesions in individuals with IPF [40]. More recently, Hubbard and colleagues found
a seven-fold increase in the incidence of lung cancer in those with IPF (termed
cryptogenic fibrosing alveolitis in their study) compared to controls, even after
adjusting for smoking [41]. These studies suggest that alterations in lung
structure/function and composition precede the development of lung cancer, which
posits one to consider that the normal, healthy lung is able to successfully defend
itself against genomic alterations due to genetic mutations.
Lung tissue remodeling can be defined as alterations in the composition and
deposition of extracellular matrix (ECM) proteins. While the ECM plays roles
consistent with the organs in which it is found, it is usually composed of similar
macromolecules; the fibrous proteins like collagens, fibronectins, laminins, and the
proteoglycans [42]. These proteins are capable of self-assembling into elaborate
and extensive, interconnected three-dimensional networks that have several roles.
The ECM provides structural support for tissues, acting as a glue and/or scaffold
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that holds cells together, but it is also has regulatory and functional roles that
determine cell shape, activity, and differentiation [43]. It is thus crucial in
maintaining tissue homeostasis. It is not surprising then that alterations in the ECM
(i.e. lung tissue remodeling) have been linked with several diseases. For example,
Ehlers-Danlos syndrome, an inherited disease marked by joint, skin, and blood
vessel problems, is caused by mutations in one or more genes that results in
defects in processing and structure of collagen. Additionally, Marfan’s syndrome is
caused by an absence of fibrillin, which leads to a lack of elastic recoil in the aorta,
predisposing individuals who suffer from this disease to aortic rupture. In terms of
the lung, tissue remodeling is one of the key features of both COPD and IPF,
diseases that are distinct, and yet that share many similarities [44,45]. For
example, in IPF, one of the main problems is excessive collagen type 1 deposition,
mainly caused by increased TGFb signaling, which leads to impaired gas
exchange [46,47]. This is also true of COPD, where ECM composition in the airway
wall has been shown to be altered compared to normal, healthy subjects [44,48].
While excessive collagen deposition is hallmark of tissue remodeling, fibronectins
are also present in large quantities in areas of fibrosis [49] and tissue repair/wound
healing [50,51]. Interestingly, alterations of the ECM have also been shown to
occur with aging, with chronic inflammation and/or oxidative stress suggested as
the possible cause [52].
Thus, while lung tissue remodeling is characteristic of COPD and IPF, both
risk factors for lung cancer, the true role that lung issue remodeling plays in lung
cancer remains undefined and further research in this area is warranted.
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1.5 Fibroblasts
Fibroblasts were first identified in the late 1800’s by their location and
appearance [53,54], and yet they remain poorly defined in molecular terms. They
are usually identified by their elongated, spindle-shaped appearance. While certain
markers in the literature are used to identify fibroblasts, there are none to date that
are known to be exclusive to fibroblasts, and there is a large variation in fibroblasts
isolated from different anatomical areas of the body. For example, desmin appears
to be a good marker for identifying fibroblasts isolated from the skin, while
discoidin-domain receptor 2 can be used to identify cardiac fibroblasts [55,56].
Fibroblasts are the predominant cell type of tissue stroma. In normal tissue
homeostasis, they are largely responsible for the production and function of the
ECM, in which they are embedded. The ECM, as described previously, functions
as a scaffold that holds cells together, but also has regulatory and functional roles
that determine cell shape and activity. Thus, fibroblasts are key players in tissue
remodeling, and have prominent roles in the development and progression of
COPD and IPF. Increased TGFb signaling is a main driver of tissue remodeling
that has proven difficult to target in diseased states due to the roles of TGFb in the
functioning of normal cells. However, it has recently been reported that specific
inhibition of TGFb signaling in lung fibroblasts could inhibit lung and tumor fibrosis
[57]. As key drivers of the development and progression of COPF and IPF, both
risk factors for lung cancer, fibroblasts also play roles in lung cancer progression
although the exacts roles and mechanisms are undefined, with contradictory
reports in the literature. For example, Yamauchi et al., showed that TIG-3
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fibroblasts, when co-implanted with lung cancer cells, increased tumor growth at
the site of injection and metastases to the lung, and that this effect was due, at
least partly, to TGFb-mediated interactions [58]. These experiments, however,
were performed in NOG mice, which are highly immunodeficient and thus must be
interpreted carefully. In contrast, others have shown that normal lung fibroblasts
play a role in inhibiting lung cancer progression. For example, Mishra et al.,
showed significantly fewer metastatic lesions in an ex vivo 4D acellular lung model
when H460 cells were seeded with normal lung fibroblasts compared to
carcinoma-associated fibroblasts (CAFs) [59]. These data, among others, point to
the complicated nature of tumor-stromal cell interactions, and warrant further
research in this area, particular in the lung.

1.6 Fibronectin
Fibronectin is a large, ubiquitously expressed, multi-domain glycoprotein
located primarily in extracellular fluids, connective tissues and on many cell
surfaces. It exists in the body in two forms: a circulating, soluble dimer form
produced mainly by hepatocytes and found in the plasma [60] (referred to as
“plasma fibronectin”) and an insoluble form produced by fibroblasts and other cells
(referred to as “cellular fibronectin”) that is embedded in fibrils in the ECM [61].
One crucial feature that distinguishes these two forms from each other is
accomplished by alternative splicing and is characterized by the inclusion of at
least one of two extra exons termed Extra Domain A (EDA) and/or Extra Domain
B (EDB) [62–64]. One or both of these domains are present in cellular fibronectin
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(cFN), but absent in plasma fibronectin (pFN). While the primary structure and
alternative splicing of fibronectin has been known for decades, the specific
functions of these isoforms have been difficult to study in vivo until recently, when
animals lacking these isoforms were developed.
Fibronectin itself plays a crucial role in embryogenesis and lung
development, evidenced by its high expression in embryonic tissues and by the
fact that animals lacking fibronectin are embryonic lethal [65,66]. Fibronectin has
roles in several cellular processes, such as hemostasis, wound healing, and host
defense. One of its most basic functions in these instances is in promoting
adhesion to and the spreading of cells on various solid substrates, such as,
collagen, fibrin, and gelatin [67–70]. For example, during wound healing, pFN exits
the damaged blood vessels, and together with other molecules and cells (e.g. fibrin
and platelets), forms a hemostatic plug that serves as a scaffold or net that
supports cell migration and re-epithelialization. Mice lacking pFN however, are still
able to heal skin wounds [71], while mice lacking fibronectin EDA are not [72],
suggesting that fibronectin EDA produced locally at the site of injury is sufficient
for wound healing. Although fibronectin has been shown to have roles in normal
wound healing, excessive fibronectin levels have been shown to promote disrepair
[36].
More recently, fibronectin has been implicated in several types of cancer
[73,74]. While fibronectin EDA has been shown to be a vascular marker for solid
tumors and metastases of the liver [75], and immunization against fibronectin EDA
in a therapeutic setting has been shown to decrease tumor burden and lung

13

metastases in the MMTV-PyMT transgenic model of metastatic mammary
carcinoma [76], little is known about its role in cancer and more specifically lung
cancer.

1.7 Oxidative Stress
The term “oxidative stress” was first proposed by Helmut Sies in 1985 as “a
disturbance in the pro-oxidant–antioxidant balance in favor of the former” [77]. This
disturbance can be due to high levels of oxidants, or low levels of antioxidants.
This definition has been useful and has led to the discovery of a number of
diseases that are associated with oxidative stress, such as cancer, diabetes, and
neurodegeneration. The main drivers of oxidative stress in these instances are
superoxide anion, hydrogen peroxide, and the hydroxyl radical, collectively termed
reactive oxygen species (ROS). There are a variety of sources of ROS in the body:
NADPH oxidases, cytokine and growth factor receptors, the electron transport
chain, and phase 2 drug metabolizing enzymes, such as xanthine oxidases and
cytochrome p450s, among others. ROS can cause reversible modifications to
protein side chains on methionine and cysteine residues. These have important
regulatory and signaling functions in the body. However, ROS can also cause
irreversible damage to macromolecules, so the body contains numerous
enzymatic (glutathione and thioredoxin) and non-enzymatic (catalase, superoxide
dismutase, glutathione peroxidase) cellular defenses to protect against these
deleterious effects. Many of these defenses are thiol-dependent. As such,
oxidative stress can now be quantified in humans as the redox state of plasma
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glutathione/glutathione disulfide (Eh GSH/GSSG) and plasma cysteine/cystine (Eh
CyS/CySS). These thiol/disulfide couples becomes oxidized with age [78], in
response to smoking, and in various diseases [79]. However, we now know that
plasma GSH redox is not in equilibrium with thioredoxin-1 or the larger
cysteine/cystine (Cys/CySS) pool. These systems also respond differently to
physiologic and chemical stimuli. These data, along with the inconsistencies of
several antioxidant trials [80–83] indicate that oxidative stress cannot be defined
by a single entity, suggesting we need to redefine the term oxidative stress. Dean
Jones at Emory University has done just that and has proposed a new definition
of oxidative stress as “a disruption of redox signaling and control.” [84] This
definition should redirect our efforts to identify key alterations in redox signaling in
oxidative stress-related diseases that will then lead to new targets for treatment.
Jones has also shown that the physiological redox potential of Cys/CySS
found in the plasma of healthy subjects is around -80 mV. In aged individuals, and
those with disease, this redox potential may be oxidized to values between -62 to
-20 mV. Our lab has previously shown that this type of oxidant stress promotes
lung fibroblast proliferation, myofibroblast transdifferentiation, and increased
expression of TGFβ in vitro [85], all of which act to create a pro-fibrotic phenotype
in the lung. These observations suggest that oxidant stress could act to create an
oncogenic microenvironment, that renders the aging host susceptible to lung
cancer progression.
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1.8 Sex
The National Institutes of Health (NIH) recently (June 2015) released a
Guide notice (NOT-OD-15-102) indicating that researchers should consider sex a
biologic variable in their studies. A quick literature review will reveal that prior to
2015, methodology detailing sex and age of most animal studies is severely
lacking. Moreover, males have been the predominant sex used in animal models
of biomedical research [86]. This has serious implications for health-care in both
men and women, as animal models in research are the predominant basis for
human clinical trials. This is unfortunate, as sex in both animals and humans has
been shown to be a determining factor in several outcomes of disease. For
example, Alzheimer’s disease and osteoporosis are more prevalent in women than
men [87,88]. In terms of pulmonary diseases, mortality from COPD in females
surpassed that of males in the year 2000 for the first time, likely due to the
increased number of females who smoke [89]. However, females do appear to be
at a greater risk of the harmful effects of tobacco smoke, when compared to males,
although this has only recently begun to be investigated [90]. Interestingly, of the
5-12% of non-smokers who are diagnosed with COPD, the vast majority are also
female [91]. These sex differences in pulmonary diseases are also observed in
several animal models. For example, in a murine model of pulmonary fibrosis,
while no differences were observed in fibrotic development, males were found to
have higher basal static lung compliance compared to females, and a significant
decline in static compliance after bleomycin instillation [92]. In rats, females were
more susceptible to mortality and fibrotic development, determined by collagen
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deposition, when compared to males [93]. This effect was abolished in
ovariectomized females without hormone replacement, and was rescued in
females given estradiol, suggesting an important role for sex hormones in the
development of pulmonary fibrosis. In contrast, female mice were found to develop
less fibrosis, as determined by hydroxyproline content, in a silica-induced lung
fibrosis model, when compared to males. This effect was again abolished in
ovariectomized females [94].
Among cancers, it is well known and descriptive epidemiological studies
have shown, that males are more prone to develop cancers, when compared to
females [95,96]. This is also true for childhood cancers, where prognosis is worse
for boys than for girls [97]. Additionally, boys who have survived cancer are at a
greater risk of secondary malignancies [98]. Among lung cancers, it has been
noted previously, that historically, men were shown to have a higher incidence rate,
but this was due to a higher frequency of smoking. It now appears that women are
actually at a greater risk of developing lung cancer compared to males [99]. For
example, women have been shown to be more susceptible to tobacco carcinogens
compared to males [100]. Although it appears that women are at a greater risk of
developing lung cancer in both smokers and nonsmokers, it has been argued that
among nonsmokers, the increased incidence among women is skewed due to a
high prevalence of lung cancer among women in Asian countries [101].
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1.9 Summary
Taken together, these data portray that population aging in the US and
worldwide is a matter of great concern and one that simply cannot be ignored.
NCDs (for the purpose of this dissertation, specifically lung cancer, IPF, and
COPD) occur almost exclusively in the elderly. Moreover, the vast majority of lung
cancers, the leading cause of cancer death in the US, also occur in the elderly and
frequently in individuals with COPD and/or IPF, diseases marked by
inflammation/tissue remodeling and oxidation of both Eh Cys/CySS and Eh
GSH/GSSG. Tissue remodeling in the elderly is marked by alterations in the
composition and deposition of extracellular matrix proteins, including fibronectin
and one of its splicing variants fibronectin EDA, which has also been shown to be
increased with aging. This dissertation explores how aging and tissue remodeling
act in concert to render the host susceptible to lung cancer progression. As the
main source of fibronectin and fibronectin EDA, we also examined what role
fibroblasts of the lung play. Finally, we examined the role of sex and oxidative
stress. These data led to the development of the following hypothesis: While
smoking and other environmental exposures can lead to lung cancer development
in a genetically susceptible individual, increased oxidation of the Eh Cys/CySS in
the aging lung creates an oncogenic microenvironment, specifically by increased
fibronectin EDA levels, that renders the host susceptible to lung cancer
progression (Figure 1).
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Figure 1. Dissertation Hypothesis
While smoking and other environmental exposures can lead to lung cancer
development in a genetically susceptible individual, we hypothesized that
increased oxidation of the Eh Cys/CySS in the aging lung creates an oncogenic
microenvironment, specifically by increased fibronectin EDA levels, that renders
the host susceptible to lung cancer progression. These events could be
exacerbated in females.
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CHAPTER II

ROLE OF AGING AND TISSUE REMODELING IN LUNG CANCER

2.1 Introduction
Cancer develops most commonly in the elderly with 78% of cancers
occurring in patients over 55 years of age [102]. This is also the case for lung
cancer, which remains the leading cause of cancer death in men and women in
the US and worldwide [2]. How exactly aging promotes cancer is unclear, but
compared to young individuals, aging is characterized by oxidant stress,
mitochondrial dysfunction, immunologic deficiencies, stem cell exhaustion, and
accumulation of damage in cells, tissues, and organs, among other things [103–
106]. Aging has also been characterized by a reduced capacity to respond to
environmental injury [107]. Yet, exactly how these processes contribute to
carcinogenesis is unknown. Interestingly, most lung cancers occur in individuals
with chronic lung disorders characterized by inflammation and tissue remodeling
such as COPD and IPF [108]. Considering the emerging data linking inflammation
and the tumor microenvironment in cancer development and progression [109], it
is not surprising that lung cancer develops most commonly in such settings.
Since the discovery of the first oncogene, Src, in 1970, and later of cellular
proto-oncogenes, the prevailing paradigm of cancer development for decades was
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that cancer arises due to mutations in oncogenes and tumor suppressor genes of
single cells. However, numerous studies performed in vitro and in vivo have now
shown that, despite malignant cell transformation, tumor growth is dependent on
processes such as inflammation and angiogenesis in the microenvironment. In
fact, it has been shown that a malignant phenotype can be reversed by using
integrin blocking antibodies [110,111]. Thus, it can be said that genetic mutations
are necessary, but not sufficient, to cause tumor growth [7]. It has been known for
some time that chronic inflammatory diseases such as COPD, asbestosis and
silicosis increase the risk of lung cancer [112]. For example, exposure to asbestos,
and the resulting inflammatory response, have been linked to lung cancer and
mesothelioma [113]. Indeed, a link between chronic inflammation and many
cancers is now well established [114] and several studies have demonstrated a
protective effect of non-steroidal anti-inflammatory drugs in cancer development
[115]. Others have found that the ability of Rous sarcoma virus to form tumors in
newly hatched chicks is dependent upon wounding and inflammation, and that the
pro-fibrotic growth factor, transforming growth factor b (TGFb), can replace
wounding as a promoter of tumor development [116].
Despite the above, the contribution of chronic tissue inflammation and
remodeling and their interaction in lung cancer have been difficult to study in
humans considering the many confounding factors present, not the least of which
is exposure to tobacco, perhaps the best known pro-oncogenic agent. It is for this
reason that scientists have turned their attention to experimental models of lung
cancer which, even though they do not exactly resemble the human condition, they
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allow for the more careful exploration of the role of individual factors.

We

hypothesized that aging and tissue inflammation/remodeling act in concert to
promote lung cancer progression, and set out to test this in a syngeneic model of
lung cancer. For this, we used aged mice, which have been shown to display
alterations in inflammatory and tissue remodeling markers [117]. Aged lungs are
characterized by, among other things, increased mRNA expression for TGFb,
matrix metalloproteinases, plasminogen activator inhibitor-1, and matrix molecules
fibronectin and collagen I [36,118]. These changes explain, at least in part, the
alterations observed in the structure of the aging lung.
One of the matrix molecules upregulated in the setting of aging is a
fibronectin splicing variant, which is characterized by the inclusion of an extra exon
termed Extra Type III Domain A (EDA). This is intriguing considering that data
generated over the past three decades have linked fibronectin with cancers
including breast, prostate, liver, and lung [119–121]. However, it has been difficult
to study the role of fibronectin in vivo mainly because animals with knockout
mutations in fibronectin are embryonic lethal [122]. More recently, animals with
knockout mutations targeting fibronectin EDA were generated and their
investigation suggests a role for this molecule in wound healing and aging [72].
Moreover, fibronectin EDA has been linked to lung inflammation and remodeling
since its deletion is protective in the bleomycin model of lung injury and repair
[123]. Considering these observations, we also tested animals lacking fibronectin
EDA.
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Our studies revealed that aged lungs were more susceptible to metastasis when
compared to young lungs.

Importantly, studies in young and aged animals

exposed to bleomycin suggest that tissue remodeling/inflammation augment
pulmonary metastasis, but only in the aging lung and not in the young lung. The
effect of bleomycin was abolished in studies performed in fibronectin EDA KO
mice, despite the presence of fibrosis. Together, these observations suggest an
interplay between lung aging and inflammation/remodeling in tumor progression,
and that fibronectin EDA is an important molecule in this setting.

2.2 Materials and Methods
2.2.1 Reagents and Cell Culture
Lewis Lung Carcinoma (LLC) cells were purchased from ATCC (CRL-1642;
ATCC, Rockville, MD) and grown in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceburg, GA) at 37 ºC in a
humidified 5% CO2 incubator. Cells were used within 3 months of resuscitation.
Bleomycin (catalog #8416) and cellular fibronectin (cFN; catalog #F2518) were
purchased from Sigma (St. Louis, MO). Sutures for surgery were purchased from
Ethicon (catalog #K833).

2.2.2 Young and Aged Animals
C57BL/6 and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice
were obtained from Jackson Laboratories and housed in pathogen-free facility at
the University of Louisville (Louisville, KY), with access to food and water ad
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libitum. Fibronectin EDA knockout mice were obtained from Dr. Eric White
(University of Michigan) and verified by PCR analysis and sequencing. All
experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Louisville.

2.2.3 LLC Model of Lung Cancer
LLC cells were split 24 hours prior to injections and were harvested in
growth phase. LLC cells were injected (1E6/100 μL sterile PBS) subcutaneously
into the hind flank of mice. In parallel experiments, animals were injected with LLC
cells intravenously (1E5 /100μL sterile PBS). Afterwards, tumors were monitored
and the length, width, and height, measured weekly, using digital calipers. A tumor
size >15mm in any direction was considered the endpoint, per IACUC regulations.
All animals were then sacrificed and tissues were harvested for analysis. The same
procedure and number of cell were performed for injections into NSG mice.

2.2.4 Bleomycin Model of Lung Injury and Repair
Bleomycin sulfate was reconstituted in sterile PBS at 1 mU/g of body weight.
Animals were anesthetized by using a mixture of ketamine and xylazine. Under
aseptic technique, the neck of the mouse was dissected and the trachea was
visualized. Bleomycin or PBS was instilled in the trachea, using a 27G needle, in
a total volume of 40 μL. The wound was sutured with black braided silk and animals
were monitored and allowed to recover on a heated pad.
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2.2.5 Tissue Processing and Histological Analysis
Per IACUC regulations, once subcutaneous tumors reached a size of 15
mm in any direction, all animals were sacrificed by CO2 administration in a closed
chamber. Lungs were flushed with PBS, inflated at standard pressure with
formalin, removed, and formalin-fixed for 48 hours. Lungs were then processed
through increasing ethanol solutions in an STP 120 Spin Tissue Processor
(ThermoFisher Scientific, Waltham, MA), paraffin-embedded, and sectioned (6
μm) using a JUNG RM2055 microtome (Leica, Buffalo Groce, IL). Lung sections
were then transferred onto charged, glass Colorfrost microslides (VWR Sciences,
Radnor, PA) for histological analysis. Sections were deparaffinized, rehydrated,
and stained with hematoxylin and eosin (HE) to evaluate lung tumors, or Masson’s
trichrome (American MasterTech, catalog #KTMTR2PT) to evaluate collagen
content for lung fibrosis determination. Five blinded reviewers used the semiquantitative Ashcroft scoring scale to score pulmonary fibrosis [124].

2.2.6 Wound Healing (Scratch Assay)
LLC cells (2.5E5) were plated in 24-well plates coated with cellular
fibronectin (10μg/mL) or plastic alone for 24 hours. A scratch was then created
using a 1 mL pipette tip. Media (2 mL) was then replaced and photographs taken
at 0 and 24 hours using an EVOSTM XL Core Cell Imaging System (AMG).
Quantification was performed using ImageJ software by measuring the distance of
the scratch in 6 separate locations at 0 and 24 hours.
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2.2.7 Analysis of Data
Means plus standard deviations of the mean were calculated for all experimental
values. Significance was assessed by using the Student's t test.

2.3 Results
2.3.1 Aging is associated with increased lung metastases
While studying a syngeneic model of lung cancer, we noticed a significant
variability in the development of lung metastasis. A retrospective analysis of the
data revealed that the age of the animals represented an important variable (not
shown). To test the role of aging prospectively, wildtype C57BL/6 mice at ages
3,5,7,9 and 12 months of age were injected subcutaneously with 1E6 LLC cells.
Tumor growth was followed until tumors reached a size of ≥15 mm, after which
time, all animals were sacrificed and lungs harvested and formalin fixed. As
depicted in Fig. 2A and 2B, mice failed to develop lung metastases until 7 months
of age or older. We observed small differences in the size of the primary tumors,
but these were not statistically significant (not shown).
To circumvent the potential confounding effects of skin immunity, we
repeated similar experiments in animals injected intravenously with the tumor cells.
In these experiments, we observed that only 50% of young (~3.5 months) mice
developed lung tumors compared to 100% of old (~12 months) mice (Fig. 2C).
Aged mice also developed a greater number of lung tumors when compared to the
number of tumors developed in the few affected young mice (Fig. 2D). Thus, aged
lungs are more susceptible to lung metastasis compared to young lungs.
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Figure 2. Aging is Associated with Increased Lung Metastases
(A,B) WT C57BL/6 mice, ages 3, 5, 7, 9 and 12 months old were injected with
1E6 WT LLC cells into the hindflank. Per IACUC regulations of endpoints, tumor
formation and size were followed until a tumor size of ≥15 mm in length or width
was established. All mice were then sacrificed and lungs harvested and processed
for examination of metastases. All mice developed tumors at the site of injection,
with no differences in size observed at day 17. (A) Percentage of mice in each
group where lung metastases were identified. (B) Number of lung metastases in
each animal in each group. (C,D) Young (3.5 months) and aged (12 months) WT
C57BL/6 mice were injected intravenously with 1E5 WT LLC cells and sacrificed
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at day 13. (C) Percentage of mice in each group where lung tumors were
identified. (D) Number of intravenous lung tumors in each animal in each group.
Aged mice developed more tumors in the lung (6.3 +/- 3.4) compared to young
mice (1.6 +/- 3.1), *P<0.05.
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2.3.2 Bleomycin treatment is associated with increased metastases, but only
in aged lungs
To examine the role of lung inflammation/remodeling in lung cancer
progression, young (~3.5 months) and aged (~9.5 months) animals were instilled
with bleomycin (1mU/g BW) followed by injection of LLC cells 14 days after
bleomycin treatment. As expected, bleomycin induced weight loss (Fig. 3A) and
lung inflammation/remodeling (Fig. 3B) in both young and aging mice. In animals
injected with LLC cells after bleomycin treatment, we again observed small
differences in the size of subcutaneous tumors at the time of euthanasia, but these
were not statistically significant (data not shown).

However, interestingly,

bleomycin augmented the number of lung metastases in the aged murine lungs,
but not in young lungs (Fig. 3C), despite the presence of inflammation/remodeling
in both groups.
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Figure 3. Bleomycin Treatment is Associated with Increased Metastases, but
Only in Aged Lungs
Young (~3.5 months) and aged (~9.5 months) WT C57BL/6 mice were instilled
intratracheally with PBS (young, n=7; aged, n=8) or bleomycin (Bleo; young, n=7;
aged, n=7). At day 14, 1E6 LLC cells were injected subcutaneously into the
hindflank. (A) Change in weight in aged mice is shown. Bleomycin significantly
induced weight loss in all mice at day 14 and day 21 post-instillation. There were
no statistically significant differences in weight loss between young and aged mice.
Mice instilled with PBS did not experience weight loss. (B) Representative HE
images depict PBS- and bleomycin-treated aged mice at 14x magnification. Tumor
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metastases are observed in all images (indicated by arrows), while fibrosis is
readily apparent in the bleomycin treated lungs. (C) Number of lung metastases in
aged mice are shown. Young mice failed to develop lung metastases in either
group, while bleomycin instillation in aged mice increased the number of lung
metastases compared to PBS (6.0 +/- 2.5 vs 1.4 +/- 1.2), *P<.05, ***P<.001.
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2.3.3 Fibronectin EDA is dispensable for aged-related lung cancer
progression,

but

required

for

bleomycin-induced

augmentation

of

metastasis
Since aged lungs show alterations in the expression of fibronectin EDA, and
fibronectin is implicated in carcinogenesis, we hypothesized that this matrix
molecule contributes to the aging effect. To test this, untreated aged wildtype and
aged fibronectin EDA knockout mice were injected with LLC cells, both
subcutaneously and intravenously. For subcutaneous tumors, growth was followed
until tumors reached a size of ≥15mm, after which time, all animals were sacrificed
and lungs harvested and formalin fixed. In the subcutaneous model, no differences
were observed in the growth of the primary tumor (data not shown) or in the
number of lung metastases (Fig. 4A) when comparing aged wildtype and aged
fibronectin EDA knockout animals. Likewise, when animals were injected
intravenously, no differences were observed in the number of lung tumors when
comparing aged wildtype and aged fibronectin EDA knockout animals (Fig. 4B).
Thus, despite being increased in aged lungs and being implicated in
carcinogenesis and cancer progression, the absence of fibronectin EDA did not
inhibit cancer progression in aged lungs in the LLC model.
To test the role of fibronectin EDA in cancer progression in the setting of
tissue remodeling/inflammation, we repeated experiments with bleomycin in aged
fibronectin EDA KO animals. Although others have reported fibronectin EDA to be
essential for the development of lung fibrosis in the bleomycin model [123], we
observed no differences in the development of bleomycin-induced fibrosis in WT
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Figure 4. Fibronectin EDA is Dispensable for Age-Related Lung Cancer
Progression
WT C57BL/6 and FN EDA KO mice were injected with 1E6 WT LLC cells into the
hindflank or 1E5 LLC intravenously. (A) Number of metastases in young WT (~2.5
months, n=5) and EDA KO (2 months, n=3) mice and in aged WT (10 months, n=5)
and EDA KO (10 months, n=3) mice. Young mice in both groups failed to develop
metastases. There were no statistically significant differences in the number of
metastases between aged WT (1.6 +/- 1.1) and aged EDA KO (4.3 +/- 4.2)
mice. (B) Number of intravenous lung tumors in aged WT and EDA KO mice are
shown. There were no statistically significant differences in the number of lung
tumors between aged WT (3.o +/- 2.5) and aged EDA KO (6.5 +/- 6.3) mice.
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and fibronectin EDA KO mice (Fig. 5A and 5B). However, interestingly, when
injected with LLC cells, the augmentation of pulmonary metastases due to
bleomycin was abolished in fibronectin EDA KO mice (Fig. 5C).
Considering the above, we hypothesized that fibronectin EDA provides a
scaffold for the proliferation, migration and organization of tumor cells within
remodeled lung tissue. This is consistent with data showing that over 75% of tumor
cells metastasizing to the lung co-localized to areas of inflammation/fibrosis (Fig.
6A and 6B). Consistent with this, LLC migration was increased on plates coated
with cellular fibronectin compared to plastic (Fig. 7A-B), and LLC proliferation was
increased when the cells were cultured in the presence of cellular fibronectin (Fig.
7C).
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Figure 5. Fibronectin EDA is Required for Bleomycin-Induced Augmentation
of Metastasis
WT C57BL/6 (~10 months) and FN EDA KO (~9 months) mice were instilled
intratracheally with PBS or bleomycin. At day 14, 1E6 LLC cells were injected
subcutaneously into the hindflank. (A) Ashcroft scores of 5 blinded reviewers. (B)
Representative trichrome stained images at 4x magnification depict lung fibrosis
of varying severity in both bleomycin treated WT and EDA KO mice. (C) Number
of lung metastases in aged mice are shown. Bleomycin increased the number of
lung metastases in WT mice (12.1 +/- 10.0 vs 33.7 +/- 8.6, ***P<.001) but not in
EDA KO mice (7.5 +/- 7.0).
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Figure 6. Lung Metastases Develop Primarily in Fibrotic Areas
Paraffin embedded sections from WT C57BL/6 mice from figure 5C were stained
with Masson’s Trichrome. (A) Representative Masson’s Trichrome stained images
at .4x and 4x magnification depict prominent lung fibrosis and LLC metastases
(green circles). (B) Percentage of LLC metastases in areas of lung fibrosis in each
individual mouse. The % of metastases that developed in fibrotic areas was greater
than 75% in all mice.
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Figure 7. Effect of cFN on LLC Proliferation and Migration
(A) LLC cells were plated on plastic or cellular fibronectin (cFN; 10µg/mL) coated
24-wellplates. (B) After 24 hours 59.1 +/- 3.2% of the initial wound area remained
on plastic vs 26.9 +/- 2.7% on cFN. *** P<.001. (C) LLC cells were plated in 48well plates in control DMEM or DMEM with 10 µg/mL cFN. ***P<.001
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2.3.4 Role of Immunity
Finally, we wanted to test the role of immunity in our model to examine if it
mediated the age-related effect on lung metastasis. For this, we injected LLC cells
into young and aged NOD scid gamma (NSG) mice, which are extremely
immunodeficient, lacking B and T cells, as well as functional NK cells. Both young
and aged mice developed tumors at the site of injection within 2 weeks, although
no differences were observed between the groups when the animals were
sacrificed at day 17 (Fig. 8A). Although the number of metastases to the lung was
greater in the aged mice, this was not statistically significant (Fig. 8B). However,
aged NSG mice developed larger metastases to the lung compared to young NGS
mice (Fig. 8C-D). The location of the lung metastases in the NSG mice also
differed from those observed in WT animals. While metastases in WT mice
developed in areas adjacent to blood vessels, this was not the case in NSG mice,
where the majority of metastases developed in the periphery of the lung (Fig 9).
These data suggest a role for innate immunity in tumor progression beyond the
primary site in the syngeneic model.
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Figure 8. Effect of Immunity on Lung Cancer Progression
(A-C) Young (2 months) and Aged (9 months) NSG mice were injected
subcutaneously into the hindflank with 1E6 LLC cells, and followed for tumor
formation. Aged WT C57Bl/6 mice were used as a third group as a positive control.
Mice were sacrificed at day 17 and lungs removed and processed for examination
of metastasis. There were no differences between groups in tumor volume at the
site of injection (A), or the number of metastases to the lung (B). Although the
number of metastases to the lung between groups was statistically unchanged,
aged NSG mice developed larger metastases (in size) to the lung (C). Graph
shows numbers of metastases in 5 groups of varying tumor size.
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Figure 9. LLC Metastases in WT and NSG Mice
Female WT C57BL/6 and female NSG mice were injected with LLC cells
subcutaneously (1E6/100µL PBS) and then followed for tumor progression. A
tumor size >15mm in any direction was considered the endpoint. Mice were then
sacrificed and lungs harvested and processed for examination of metastases.
Representative HE-stained lung images showing lung metastases at 10X are
shown. Black arrows indicate metastases.
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2.4 Discussion
By the year 2020, it is estimated that 70% of all neoplasms will occur in
individuals aged 65 years or older [125]. Among them, lung cancer remains the
deadliest and occurs most commonly in individuals with chronic lung disorders
characterized by inflammation and tissue remodeling such as chronic obstructive
pulmonary disease and fibrosis [108]. The relative contribution of these processes
to the pathogenesis of lung cancer, especially metastatic disease, has been
difficult to study in part because of the concomitant exposure to tobacco, a wellknown carcinogen [126]. Thus, we set out to study the role of aging and lung tissue
inflammation/remodeling in an experimental syngeneic model of lung cancer.
Several observations were made as summarized below.
First, we observed that aged lungs develop more metastatic lesions than
young lungs, resembling the human condition. This was observed when LLC cells
were injected subcutaneously or intravenously, which suggests that some inherent
factor(s) in the aged lungs is responsible for this susceptibility, and not tumor
implantation, growth, or metastasis from the primary tumor, nor does it relate to
the ability of cancer cells to escape the immune system in the periphery. These
data contribute to the notion that malignant cell transformation alone is not
sufficient for tumor growth and progression. Young, healthy, immunocompetent
animals are able to mount a successful defense in the lung to protect against lung
lesions. However, aging appears to render the lung vulnerable to cancer
progression.
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Second, we showed that lung tissue inflammation/remodeling was
associated with increased lung metastases, but only in aged animals suggesting
an interplay between aging and lung injury. In our hands, bleomycin induces
fibrosis in both young and aged mice, with aged mice showing greater injury [36].
Young mice, however, still failed to develop lung metastases, which suggests that
inflammation and/or tissue remodeling is not sufficient for cancer progression in
our model. In light of the fact that aged mice show greater injury in response to
bleomycin, it remains to be determined if increased inflammation or increased
fibrosis contributes to the increased susceptibility to lung cancer. Independent of
its role, the amount of fibrosis detected cannot fully explain the differences
observed.
Third, we observed that, even though fibronectin EDA is increased in aging
lungs and has been implicated in cancer, this matrix molecule was not required for
cancer progression in normal lungs. Fibronectin EDA has been shown to be a
vascular marker for solid tumors and metastases [75], and immunization against
fibronectin EDA in a therapeutic setting has also been recently shown to decrease
tumor burden and lung metastases in the MMTV-PyMT transgenic model of
metastatic mammary carcinoma [76]. Based on these observations, we
hypothesized that the aging lung contains a pro-oncogenic microenvironment due
to increased levels of fibronectin EDA that renders the host susceptible to lung
cancer progression. However, this was not found to be the case in our model. We
found tumors in lung even in fibronectin EDA knockout mice suggesting that this
matrix molecule is not required for lung metastasis.
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Fourth, although fibronectin EDA could not explain the increased
susceptibility to lung metastasis in the aging lung, it was required for the
augmentation of lung metastasis in response to tissue injury induced by bleomycin.
Of interest was the fact that, despite a report in the literature that fibronectin EDA
is essential for bleomycin induced lung fibrosis, in our hands, fibronectin EDA KO
mice developed as much bleomycin-induced lung fibrosis as WT animals. This
might be related to differences in the age of animals used, and dose and batch of
bleomycin administered. Nevertheless, we did not observe an augmentation of
lung metastasis in response to bleomycin in fibronectin EDA KO animals, which
suggests that this matrix molecule plays an important role in lung cancer
progression in the setting of aging coinciding with tissue remodeling/inflammation.
Several mechanisms may explain the pro-oncogenic effects of fibronectin EDA as
it may serve as a scaffold for the proliferation, organization, and migration of tumor
cells.
Finally, we observed that both young and aged NSG mice developed
tumors at the site of injection, and metastases to the lung in the LLC model.
Although there were a greater number of metastases in the aged NSG mice, this
was not statistically significant. However, aged NSG mice had larger tumors in
their lungs compared to young NSG mice. The location of metastases in the NSG
mice also differed from those observed in WT mice. These data suggest that the
increased number of metastases observed in aging WT mice is somehow
dependent on alterations in immune responses involving B, T and NK cell – related
mechanisms. This could possibly be due to decreased T-cell dependent functions,
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which have been shown to decline with aging [105,127,128]. This will require
further investigation.
Overall, we report that aging acts in concert with lung injury to further
increase the risk of lung cancer progression. This work adds to a growing body of
literature implicating both aging and lung injury as risk factors for lung cancer
development and progression [129]. While aging is thought to promote lung cancer
progression through immune-mediated factors, the amplifying effects of lung injury
in aging appear dependent on fibronectin EDA. These data, along with those of
Sueblinvong, et al. [36], suggest that young mice are able to successfully repair
bleomycin-induced lung injury, while old mice are predisposed for disrepair, and
thus more susceptible to lung cancer progression. Our data suggest that this
aberrant repair in the aged lung is facilitated by fibronectin EDA, which is not only
increased in the aging lung, but also increased in the aging lung in response to
bleomycin, when compared to young lungs. It is important to note that these
mechanisms may vary in different cancers as aging does not appear to affect
tumor progression similarly when different tumors are tested [130].
Taken together, our data suggest that age-dependent host immune factors
influence lung cancer progression. Importantly, lung inflammation and tissue
remodeling augment pulmonary metastasis in the aging lung, but not in young
lungs, through mechanisms involving fibronectin EDA, which perhaps provides a
scaffold for tumor cell migration, organization, and proliferation. This points to an
interplay between lung aging and inflammation/remodeling in lung tumor
progression. Admittedly, strategies for targeting fibronectin in the clinic would be
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limited due to the high concentration of fibronectin in the plasma and other organs,
but much work is being done in this area [131]. Perhaps a better approach would
be to target fibronectin recognition by blocking its association with its various
integrins [132]. This report underscores the need for further studies in this area to
unveil new anti-lung cancer therapies.

46

CHAPTER III

ROLE OF FIBROBLASTS IN LUNG CANCER

3.1 Introduction
Although the incidence of lung cancer has decreased over the past decade,
it still remains higher than that of breast cancer, prostate cancer, and colon cancer
combined [2], and remains a significant threat worldwide [133]. Tobacco use
remains the number one risk factor, exposing an individual to a myriad of
carcinogens, among other harmful compounds [126]. The prevailing paradigm for
decades has been that cells, when exposed to these and other carcinogens,
acquire mutations in vital genes that over time lead to the development of tumors
[134]. However, it is now well-documented that mutations alone are not sufficient
to account for tumor development and progression [7]. In fact, a decreased
incidence of colon and breast cancer has been observed through the use of nonsteroidal anti-inflammatory drugs [135,136], which suggests that factors other than
cellular transformation are needed to cause tumor growth. This concept was first
proposed in 1889, when Stephen Paget revealed his seed and soil hypothesis,
which described a non-random pattern of metastasis in which cancer cells
(“seeds”) depend on crosstalk with the microenvironment (“soil”) for growth and
progression. In other words, metastasis from a primary tumor to distant organs is
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site specific, where the soil produces molecular factors appropriate and necessary
for the seed’s survival. Since then, it has been shown that processes such as
inflammation, angiogenesis, and paracrine signaling from stromal cells in the tumor
microenvironment are vitally important for tumors to survive and progress [137].
Fibroblasts are a predominant cell type in the tissue microenvironment and
are largely responsible for the production of the extracellular matrix, in which they
are embedded. Much attention has been given to the role of cancer-associated
fibroblasts, which have been termed activated fibroblasts, identified by their
expression of alpha-smooth-muscle actin [138]. It is well-known that these
activated fibroblasts can promote tumor progression. However, the role that normal
lung fibroblasts play in the progression of lung cancer has been difficult to
ascertain, with conflicting reports in the literature. For example, Yamauchi et al.,
showed that TIG-3 fibroblasts, when co-implanted with lung cancer cells, increased
tumor growth at the site of injection and metastases to the lung, and that this effect
was due, at least partly, to TGFb-mediated interactions [58]. These experiments,
however, were performed in NOG mice, which are highly immunodeficient and thus
must be interpreted carefully. In contrast, others have shown that normal lung
fibroblasts play a role in inhibiting lung cancer progression. For example, Mishra
et al., showed significantly fewer metastatic lesions in an ex vivo 4D acellular lung
model when H460 cells were seeded with normal lung fibroblasts compared to
carcinoma-associated fibroblasts [59]. Others have shown an important role of
fibroblast-derived hepatocyte growth factor (HGF) in lung cancer progression
[139,140]. This has largely been shown in the setting of resistance to epidermal
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growth factor receptor tyrosine kinase inhibitors [141,142]. These data, among
others, point to the complicated nature of tumor-stromal cell interactions, and
warrant further research in this area. Even fewer studies have examined the role
of young versus aged fibroblasts in terms of lung cancer. With the emerging
practice of personalized medicine based on a patient’s genetic profile, perhaps the
conflicting reports in the literature could be explained, at least in part, to differences
in the genetic profile of the host and/or the various lung cancer cell lines used.
Here, we attempt to assess the role that normal, untransformed fibroblasts
of the lung play in lung cancer progression in vitro and in vivo in immunocompetent
animals using human and murine lung fibroblast and lung cancer cell lines. We
also explore the effect of aging, by using primary lung fibroblasts isolated from old
animals.

3.2 Materials and Methods
3.2.1 Reagents
Transwell inserts with an 8.0 µm pore size were purchased from Corning
(Costar, catalog #3464). All chemical reagents were purchased from Tocris
Bioscience (Ellisville, MO) unless otherwise specified. The cell transformation
detection assay (colony formation) kit was obtained from Millipore (Temecula, CA,
catalog #ECM570). The Cell Titer-Glo® Luminescent Cell Viability Assay (catalog
#G7572) and Caspase-Glo® 3/7 Assay (catalog #G8091) were obtained from
Promega (Madison, WI).
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3.2.2 Cell Culture
Lewis Lung Carcinoma (LLC) (CRL-1642), A549 (CCL-185), H1792 (CRL5895), H460 (HTB-177), WI38 (CCL-75), and IMR90 (CCL-186) cells were
purchased from ATCC (Rockville, MD). Primary murine lung fibroblasts (PLF) were
isolated by harvesting lungs from 3-month-old (young) or 24-month-old (old)
C57BL/6 mice. Lungs were minced and allowed to attach to a p100 dish by air
drying for 5 minutes. Five mL of DMEM were then gently added. All cells were
grown in DMEM supplemented with 10% FBS, at 37 ºC in a humidified 5% CO2
incubator.

3.2.3 Fibroblast Conditioned Media
Primary murine lung fibroblasts (1.5E6) were plated in p150 dishes in 25
mL DMEM with 10% FBS, and allowed to grow for 3 days. For controls, 25 mL
DMEM was added to p150 dishes with no cells and incubated for 3 days. Media
was then collected from all groups into 50 mL conical tubes and spun at 1000 RPM
for 5 minutes, filtered (0.2 μM), and then transferred to new 50 mL conical tubes
and stored at -70ºC until future use. The same protocol was used from IMR90 and
WI38 fibroblasts, but 1.5E6 and 1E6 cells were plated in p100 dishes in 15 mL
DMEM, respectively.

3.2.4 Morphology
LLC (100/100 µL-well), A549 (1000/100 µL-well), H1792 (1500/100 µL-well)
and H460 (1000/100 µL-well) cells were plated in clear 96-well plates and cultured
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in control DMEM or FCM for 5 days. Cells were then formalin fixed by adding warm
4% paraformaldehyde for 10 minutes. Cells were washed with PBS and
permeabilized with 1% Triton X-100 (PBS) for 5 minutes. Cells were again washed
with PBS. Cells were stained with phalloidin for 1 hour at room temperature,
followed by DAPI staining for 1 minute. Cells were then photographed using an
EVOSTM FL digital inverted fluorescence microscope (AMG, AMEFC-4302).

3.2.5 Western Blot Analysis
For protein isolation, all cells were plated in 6-well plates and incubated 24
- 120 hours. Some experiments included a 24-hour serum starvation period prior
to treatment. After treatment, cells were washed with PBS and collected into 1.5mL
Eppendorf tubes in PBS via scraping. No trypsin was used. Cells were then
centrifuged at 750 x g and resuspended in homogenization buffer containing 50
mM NaCl, 50 mM NaF, 50 mM NaP2O7-10 H2O, 5 mM EDTA, 5 mM EGTA, 2 mM
Na3VO4, 0.5 mM PMSF, 0.01% Triton X-100, 10 mM HEPES, pH 7.4. Samples
were placed on ice and then sonicated with 3 quick pulses using a Sonifier 450
(Branson, Danbury, CT). Protein concentrations were determined using Bradford
reagent (Sigma) readings in DU-800 Spectrophotometer (Beckman Coulter, Brea,
CA) in a 96-well format. Protein (20 µg) was mixed with 5X sample buffer and water
to an equal volume for all samples, heated at 90 ºC for 5 minutes, briefly
centrifuged, and then loaded into 10-well, 10% SDS polyacrylamide gels (8% for
FN). Gels were run in a mini trans-blot system (Bio-rad), on ice, at 100-150V for 2
hours, using a Powerpack HC power supply (Bio-rad). Gels were then soaked in

51

Pierce Transfer Buffer (Thermo Scientific) for 15 minutes. Protein was transferred
to 0.2 µm Nitrocellulose Membranes (Bio-rad) using a Trans-Blot SD semi-dry
transfer cell (Bio-rad) at 25V for 1.5 hours. Membranes were then air dried for 15
minutes and blocked for 1 hour at RT in Odyssey Blocking Buffer (PBS, Li-Cor).
Membranes were then incubated overnight at 4ºC with the primary antibodies
against GAPDH (Sigma; 1:10,000), fibronectin (Sigma, 1:1000), e-cadherin (CellSignaling, 1:500), vimentin (Cell-Signaling, 1:500), alpha smooth muscle actin
(Abcam, 1:1000). Membranes were washed (3 x 10 minutes) with PBST and then
incubated with the appropriate secondary antibody (1:20,000) for 1 hour at RT.
Membranes were again washed in PBST (3 x 10 minutes). Florescent blots were
then scanned on a LI-COR Odyssey CLx imaging system and analyzed in Image
Studio (LI-COR).

3.2.6 Proliferation Assay
LLC (100/500 µL-well), A549 (1000/500 µL-well), H1792 (1500/500 µL-well)
and H460 (1000/500 µL-well) cells were plated in clear 48-well plates and cultured
in control DMEM or FCM, and allowed to grow up to 7 days. Media was replaced
every 2-3 days. Cell proliferation was then evaluated using the CellTiter-Glo®
Luminescent Cell Viability Assay. Briefly, media was aspirated and 100µL
CellTiter-Glo lysis buffer was added. Plates were shaken for 1 minute, incubated
for 8 minutes at room temperature, and then shaken an additional minute. Seventyfive µL was then transferred to an all-white 96-well plate and read using a
Luminoskan Ascent Luminometer (Beckman Coulter).
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3.2.7 Transwell Migration Assay
LLC, A549, H1792, and H460 cells (all at 50,000/200 µL) were plated into
Transwell inserts in 200 µL serum free DMEM in 24-well plates. Complete DMEM
or FCM (700 µL) was pipetted into the bottom of the well to act as a
chemoattractant. Inserts were removed 16 hours later (24 hours for LLC cells) and
cells were fixed and stained using Thermo Scientific’s Kwik-Diff kit (catalog
#9990700), per the manufacturer’s instructions. Inserts were then rinsed in dH2O
and non-adherent cells on the inside of the insert were removed with a cotton
swab. Cells were then photographed using an EVOSTM XL Core Cell Imaging
System (AMG).

3.2.8 Colony Formation Assay
The colony formation assay was performed according to Millipore’s
instructions (Cell Transformation Detection Assay, ECM570). Briefly, a 0.8% base
agar layer was prepared (500 μL/24-well) by boiling the agar in dH2O and allowed
to cool for 5 minutes. An equal amount of DMEM was then added and plated out.
Plates were placed at 4ºC for at least 30 min to allow the base agar layer to gel.
The top agar (0.4%) layer (200µL) was prepared by mixing 0.8% solution with
equal amount of culture media. Plates were incubated at 37ºC for 5 minutes prior
to addition of cells (500-1000/well) followed by incubation for up to 21 days. Control
media or FCM (250 μl/well) was added and then replaced every 3-4 days, after
aspiration of old media. Afterwards, colonies were photographed and counted
using ImageJ software.
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3.2.9 Wound Healing (Scratch) Assay
LLC (5E5/5 mL DMEM), A549 (7.5E5/5 mL DMEM), H1792 cells (1E6/5
mL DMEM) and H460 cells (1E6/5 mL DMEM) were plated into 6-well plates.
After 24 hours, cells were scratched with a sterile 1 mL pipette tip. Media was
then aspirated and replaced with 5 mL control DMEM or FCM. Media was
replaced at 24 hours. Photographs were taken at 0 and 48 hours using an
EVOSTM XL Core Cell Imaging System (AMG). Quantification was accomplished
using ImageJ software, by measuring the distance of the scratch area in three
separate locations at 0 and 48 hours.

3.2.10 Caspase 3/7 Activation Assay
LLC (3000/100 µL-well), A549 (5000/100 µL-well), H1792 (5000/100 µLwell) and H460 (5000/100 µL-well) cells were plated in white-walled, clearbottom, 96-well plates and cultured in control DMEM or FCM for 24 hours. Media
was then aspirated and 50 µL of control DMEM or FCM with or without cisplatin
was added. Final concentrations of cisplatin were 10, 30, 30 and 100 µM for LLC,
A549, H460 and H1792, respectively. Apoptosis was then evaluated using the
Caspase-Glo® 3/7 Assay. Briefly, 50 µL Caspase-Glo® lysis buffer was added.
Plates were shaken for 2 minutes, incubated for 1 hour at RT, shaken an
additional 2 minutes, and then read using a Luminoskan Ascent Luminometer
(Beckman Coulter). Cell viability was evaluated using the CellTiter-Glo®
Luminescent Cell Viability Assay as described above.

54

3.2.11 Animal Studies
All experiments were approved by the Institutional Animal Care and Use
Committee of the University of Louisville. LLC cells and primary lung fibroblasts
were plated out 24 hours prior to injections and were harvested at ~50%
confluence to ensure cells were in growth phase. LLC cells (1E6 /100 μl sterile
PBS) were injected alone or together with primary lung fibroblasts (1E6 /100 μl
sterile PBS) subcutaneously into the hind flank of wildtype C57BL/6 mice.
Afterwards, tumors were monitored and measured weekly. A tumor size >15 mm
in any direction was considered the endpoint, per IACUC regulations. Animals
were then sacrificed and tissues were harvested for analysis. In separate
experiments, LLC cells (1E6) that had been grown in control DMEM or FCM for 24
hours were then injected into the hindflank in control DMEM or FCM and followed
as described above.

3.2.12 Tissue Processing and Histological Analysis
Animals were sacrificed by CO2 administration in a closed chamber. Lungs
were flushed with PBS, inflated at standard pressure with formalin, removed, and
formalin-fixed for 48 hours. Lungs were then processed through increasing ethanol
solutions in an STP 120 Spin Tissue Processor (ThermoFisher Scientific,
Waltham, MA), paraffin-embedded, and sectioned (6 μm) using a JUNG RM2055
microtome (Leica, Buffalo Groce, IL). Lung sections were then transferred onto
charged, glass Colorfrost microslides (VWR Sciences, Radnor, PA) for histological
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analysis. Sections were deparaffinized, rehydrated, and stained with hematoxylin
and eosin (HE) to evaluate lung tumors.

3.2.13 FCM Characterization via Antibody Array
A RayBio label-based (L-series) mouse antibody array L-308 membrane kit
(# AAM-BLM-1-4) was used for FCM characterization, per the manufacturer’s
instructions. Briefly, samples were dialyzed by loading 3 mL control DMEM and
3mL FCM each into 2 dialysis vials, and then placed in 4 L PBS overnight at 4ºC.
Samples were then transferred to 5 mL Eppendorf tubes and spun at 10,000 RPM
for 5 minutes and transferred to new Eppendorf tubes. Labeling reagent was added
and samples were incubated at room temperature for 30 minutes with gentle
shaking. Stop solution was then added and samples were spun at 1000 x g for 3
minutes using the provided spin columns. Membranes were blocked in provided
blocking buffer for 1 hour at room temperature with gentle shaking. Samples were
diluted 1:2 by mixing 5 mL sample with 5 mL blocking buffer. Membranes were
then incubated at room temperature for 2 hours with gentle shaking. Membranes
were washed three times per ten minutes with wash buffer #1 and three times per
ten minutes with wash buffer #2. 500x HRP-conjugated streptavidin was diluted
with 10 mL blocking buffer and membranes were incubated for 2 hours at room
temperature. Membranes were then washed and exposed to detection buffer for 2
minutes with gentle shaking. Membranes were placed between provided plastic
sheets and imaged using Biorad’s ChemiDoc™ XRS+ System.

56

3.2.14 Analysis of Data
Means plus standard deviations of the mean were calculated for all
experimental values, unless otherwise noted. Significance was assessed by using
the Student's t test, unless otherwise noted. All experiments were repeated a
minimum of 3 times with each sample group containing a minimum number of three
experimental groups.

3.3 Results
3.3.1 FCM alters morphology of lung cancer cells
Lung cancer cells were cultured in complete DMEM versus fibroblastconditioned media (FCM) for 5 days. FCM was obtained from IMR90 and WI38
human lung fibroblasts when testing human cancer cells, and from primary murine
lung fibroblasts when testing LLC cells. Afterwards, cells were formalin fixed,
permeabilized, and stained with phalloidin and DAPI. FCM altered the morphology
of A549, H1792, and LLC cells, but not H460 cells (Fig. 10A-D). This change in
morphology was characterized by a spindle shape appearance, and was
accompanied by cell scattering, both of which suggested the possibility of
epithelial-mesenchymal transition (EMT), a marker of increased metastatic
potential. To test this, cells were serum starved for 24 hours and then cultured in
complete DMEM or FCM for 48 hours. Protein was then isolated, followed by
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Figure 10. FCM Alters Lung Cancer Cell Morphology
A549, H1792, H460, and LLC cells were grown in 96-well plates in control DMEM
or FCM for 5 days, formalin fixed, permeabilized and stained with phalloidin and
DAPI. FCM altered the morphology of all cell lines, with the exception of H460
cells. Cell-scattering and a spindle-shaped morphology was observed.
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Western Blot analysis for vimentin, E-cadherin, alpha smooth-muscle actin, and
fibronectin. Very small changes were noted in all cell lines, except for H1792 cells,
were alpha smooth-muscle actin, vimentin, and fibronectin levels were all
increased in response to FCM (Fig. 11A-D).
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Figure 11. Effect of FCM on EMT Markers
A549, H1792, H460, and LLC cells were grown in 6-well plates in control DMEM
or FCM for 24 hours, serum starved for 24 hours, and then grown in FCM for an
additional 48 hours. Protein was isolated, followed by Western Blot analysis (20
µg) for fibronectin (FN, 1:1000), E-cadherin (Ecad, 1:500), Vimentin (Vim, 1:500),
alpha smooth muscle actin (aSMA, 1:1000), and GAPDH (loading control,
1:10,000).
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3.3.2 FCM has differential effects on proliferation, migration, and colony
formation
To examine the effects of FCM on lung cancer cell proliferation, cells were
cultured in complete DMEM or FCM for up to 7 days. All cell lines cultured in FCM
showed increased proliferation, as determined by ATP quantification, when
compared to cells grown in complete DMEM (Fig. 12A-D). Likewise, Transwell
migration was increased in all cell lines (Fig. 13A-D), as determined by Boyden
chamber migration assays, with the greatest effect being observed in H1792 cells.
Additionally, colony formation of A549 cells was increased by the presence of FCM
(Fig. 14A) but was unchanged in H1792 and H460 cells (Fig. 14B-C), while a
decrease was observed in LLC cells (Fig. 14D). Lastly, wound healing, as
determined by the scratch assay, was increased in A549, H1792 and LLC cells
cultured in the presence of FCM, again, with the greatest effect being observed in
H1792 cells. (Fig. 15A, B and D). Interestingly, FCM had no effect on wound
healing in H460 cells (Fig. 15C).
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Figure 12. FCM Increases Lung Cancer Cell Proliferation
A549, H1792, H460, and LLC cells were grown in 48-well plates in control DMEM
or FCM for 7 days. Cells were refed every 2-3 days. Cell proliferation was
quantified using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega).
Graphs depict relative luciferase units (RLU). Cell proliferation was increased in all
cell lines tested in response to FCM. ***P<.001.
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Figure 13. FCM Increases Transwell Migration
A549, H1792, H460, and LLC cells (50,000) were plated in a Transwell Boyden
inserts in serum- free media (200 µL) with control DMEM, IMR90 FCM, or WI38
FCM in the lower well (700 µL). After 20-24 hours, cells were fixed and stained
using the Kwik-Diff kit (Thermo Scientific). Inserts were then rinsed in dH2O and
non-adherent cells on the inside of the insert were removed with a cotton swab
and photographed. Transwell migration was increased in all cell lines tested in
response to FCM.
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Figure 14. Effect of FCM on Colony Formation
A549, H1792, H460, and LLC cells plated in 24-well plates were suspended in
0.4% top agar layer and plated on a 0.8% base agar layer, which was prepared
according to Millipore’s instructions. Control DMEM or FCM was then added.
Media was replaced every 3-4 days. Colonies were followed for 14 days and then
counted and quantified using ImageJ software. Colony formation was increased in
A549 cells and decreased in LLC cells in response to FCM, while no changes were
observed in H1792 or H460 cells. *P<.05
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Figure 15. Effect of FCM on Wound Healing
A549, H1792, H460, and LLC cells were plated in 6-well plates and allowed to
grow overnight. A scratch was then created using a 1 mL pipette tip. Media was
replaced with 5 mL control DMEM or FCM (10 mL for LLC cells). Photographs
taken at 0 and 48 hours. Quantification was performed using ImageJ software.
Wound healing was increased in all cell lines tested in response to FCM, except in
H460 cells. Numbers indicate % closure after 48 hours.
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3.3.3 FCM protects against cisplatin-induced death
To evaluate the role of FCM in cisplatin-induced death, lung cancer cells
were cultured in control DMEM or FCM for 24 hours. Cells were then exposed to
cisplatin for an additional 28 hours. There was a significantly greater number of
viable cells, after cisplatin exposure, when the cells were cultured in FCM
compared to complete DMEM (Fig. 16A-D). FCM-induced cisplatin protection was
accompanied by a decrease in the activity of caspases 3 and 7 in all cells (Fig.
17A,B and D), while no changes were observed in H460 cells (Fig. 17C). A
summary of the in vitro findings is provided in Table 1.
Table 1. Effect of FCM
Morphology
Proliferation
Transwell Migration

A549
Altered
Increased
Increased

H1792
Altered
Increased
Increased

Colony Formation
Scratch Migration
Apoptosis Resistance

Increased
Increased
Increased

No Change No Change Decreased
Increased
No Change Increased
Increased
Increased
Increased
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Figure 16. FCM Decreases Sensitivity of Lung Cancer Cells to Cisplatin
A549, H1792, H460, and LLC cells were plated in white-walled, clear-bottom 96well plates in control DMEM or FCM and allowed to grow overnight. Cisplatin
(30µM, 100 µM, 30µM, and 10 µM, respectively) was then added and cells were
allowed to grow an additional 24 hours. The remaining viable cells were quantified
using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega). Graphs depict
% of control cells that did not receive cisplatin. Units are relative luciferase units
(RLU). All cell lines tested showed a decreased sensitivity to cisplatin in response
to FCM, with a greater effect being observed in H1792 and LLC cells.
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Figure 17. Effect of FCM on Caspase 3/7 Activation
A549, H1792, H460, and LLC cells were plated in white-walled, clear-bottom 96well plates in control DMEM or FCM and allowed to grow overnight. Cisplatin
(30µM, 100 µM, 30µM, and 10 µM, respectively) was then added and cells were
allowed to grow an additional 24 hours. Caspase 3/7 activity was then detected
using the Caspase-Glo 3/7 Assay Kit (Promega). Graphs depict % of control cells
that did not receive cisplatin. Units are relative luciferase units (RLU). Caspase 3/7
activation was decreased in all cells lines tested in response to FCM, except H460
cells. ***P<.001.
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3.3.4 Fibroblasts co-injected with LLC cells promote tumor growth, while
FCM has small affect
Having established the effects of FCM on lung cancer cells in vitro, we
focused our attention on the role of fibroblasts in vivo. First, primary lung fibroblasts
and LLC cells were grown separately until cells were in exponential growth phase.
Cells were then co-injected into the hindflank of C57BL/6 mice. Tumor growth was
followed until tumors reached a size of 15 mm in any direction, after which time, all
animals were sacrificed and lungs were harvested and formalin fixed. Primary lung
fibroblasts and LLC cells injected together caused larger tumor growth at the site
of injection at 18 days (sacrifice), compared to LLC cells alone (Fig. 18A). Primary
lung fibroblasts injected alone did not cause tumors at the site of injection (data
not shown). To evaluate lung metastasis, lungs were processed, paraffin
embedded, sectioned, and H&E stained. As depicted in Fig. 18B, there were no
differences in lung metastasis observed.
To evaluate the role that FCM plays in lung cancer metastasis, we grew
LLC cells in FCM for 24 hours and then injected them into the hindflank of C57BL/6
mice in FCM or complete DMEM. Tumor growth was again followed until tumors
reached a size of 15 mm in any direction, after which time, all animals were
sacrificed and lungs were harvested and formalin fixed. Although the number of
metastases in the FCM group was greater in number than those in the complete
DMEM group (2.6 vs 4.5), this was not statistically significant (Fig. 18D). Tumor
size at the site of injection was also unchanged (Fig. 18C).
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Figure 18. Effect of PLF and FCM on Tumor Growth and Lung Metastasis In
Vivo
(A,B) 1E6 LLC cells (LLC, n=6) or 1E6 LLC cells with 1E6 PLF cells (LLC+PLF,
n=7) were injected subcutaneously into the hind flank of WT C57BL/6 mice. (C,D)
LLC cells were grown in control DMEM or FCM for 24 hours and then injected
subcutaneously into the hind flank of WT C57BL/6 mice. A tumor size of ≥15mm
in length or width was established as the endpoint according to IACUC regulations.
Mice were then sacrificed and lungs harvested and processed for examination of
metastases. Tumor volume was greater in the LLC+PLF group compared to LLC
cells alone (A), while no differences in the number of lung metastases were
observed (B). Tumor volume (C) and lung metastasis (D) was similar in animals
injected with LLC cells grown in complete DMEM vs. FCM. *P<.05.
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3.3.5 FCM Characterization
In order to identify the soluble component(s) present in FCM responsible for
the observed effects, we began by utilizing Corning® Spin-X® UF Concentrators to
determine the relative size of the ‘active’ agent. Using columns with a molecular
weight cutoff of 100 kDa, we were able to block the effects of FCM, with the
exception of the protection from cisplatin-induced apoptosis, which indicates that
most of the effects of FCM are due to factors greater than 100 kDa in size (not
shown). Other studies suggested that the activity was not mediated by molecules
capable of interacting with RGD-binding integrins, as RGD peptides (used at 500
ug/ml) did not block the effect. Heparin, boiling (100 ºC, 10 minutes), and proteases
(PMSF), also failed to inhibit the activity suggesting that the soluble factor(s) in
FCM is either not a protein, or a protein in a multiprotein complex, which protected
it from degradation.

Lastly, several antagonists for fibroblast growth factor

receptors (SU 6668, PD161570, and FIIN1 HCl), a well characterized mitogen of
fibroblasts, also failed to inhibit the activity of FCM on proliferation (not shown).
For a more targeted approach, we used RayBio AAM- BLM-1 label-based
mouse antibody array, which simultaneously measures the expression of 308
soluble murine proteins. Fifteen different proteins were identified in FCM that were
not present in complete DMEM (Fig. 19). One of these proteins is hepatocyte
growth factor (HGF) and is 105 kDa in size that is cleaved by serine proteases into
a 69-kDa alpha-chain and 34-kDa beta-chain.

To determine if HGF was

responsible for the observed effects of FCM on lung cancer cells, we tested the
effects of a commercially available hepatocyte growth factor receptor (cMet)
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Figure 19. FCM Characterization
A RayBio label-based (L-series) mouse antibody array L-308 membrane kit (#
AAM-BLM-1-4) was used for FCM characterization. Control DMEM or FCM
samples were dialyzed and biotin labeled and then incubated with membranes
containing 308 soluble mouse protein antibodies. Membranes were then washed
and exposed to HRP-conjugated streptavidin, followed by ECL and then imaged
using Biorad’s ChemiDoc™ XRS+ System. Red boxes indicate proteins present in
FCM that were not present in complete DMEM (see list).
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antagonist, PF 04217903 mesylate. The presence of PF 04217903 prevented the
change in tumor cell morphology induced by FCM, except for in LLC cells, and
blocked many, albeit, not all, of the effects of FCM (Table 2). However, in all cell
lines, it was unable to block the mitogenic effect of FCM, as well as the protective
effect of FCM on cisplatin-induced apoptosis.
Table 2. Effect of
FCM + cMET
Antagonist
Morphology
Proliferation
Transwell
Migration
Colony Formation
Scratch Migration
Apoptosis
Resistance

A549

H1792

H460

LLC

Blocked
Blocked
No Change No Change
Blocked
Blocked

No Change
No Change
No Change

No Change
No Change
No Change

No Change No Change
Blocked
Blocked
No Change No Change

No Change
No Change
No Change

Blocked
No Change
No Change

To further investigate the identity of the component in FCM responsible for
the effects on proliferation and cisplatin resistance, we charcoal stripped the FCM.
Interestingly, the effects of FCM on cisplatin resistance were abolished with
charcoal-stripped FCM (Fig. 20A-C). These data suggest that the components in
FCM responsible for increasing resistance to cisplatin are non-polar materials such
as lipids.
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Figure 20. Charcoal-Stripped FCM Blocks Protection Against Cisplatin.
A549, H1792, H460, and LLC cells were plated in white-walled, clearbottom 96-well plates in control DMEM or FCM and allowed to grow overnight.
Cisplatin (30µM, 100 µM, 30µM, and 10 µM, respectively) was then added and
cells were allowed to grow an additional 24 hours. The remaining viable cells were
quantified using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega). All
cells lines tested showed a decreased sensitivity to cisplatin in response to FCM,
with a greater effect being observed in H1792 and LLC cells.
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3.4 Discussion
The prevailing paradigm of cancer for decades has been that a cell acquires
mutations over its lifespan that eventually lead to a malignant phenotype and the
development of cancer. However, this paradigm does not tell the entire story, and
we now know that stromal cells in the tumor microenvironment are not idle
bystanders, but co-evolve with transformed cells and play a crucial role in cancer
progression. To date, the vast majority of research in this area has focused on the
role of tumor or carcinoma-associated fibroblasts [143–145], and thus it has
focused on what occurs after the tumor has already developed. Fewer studies
have examined the role of normal lung fibroblasts, and thus what precedes tumor
development. We hypothesized that normal, unstimulated fibroblasts of the lung
also represent an important component of the tumor microenvironment that helps
drive tumor progression, and that old fibroblasts would have an even greater effect
on lung cancer cells. Consistent with this hypothesis, our studies show that normal
lung fibroblasts produce a soluble substance(s) capable of altering cancer cell
morphology and stimulating proliferation, migration, and colony formation of
several NSCLC lines, as well as protecting against cisplatin-induced apoptosis in
vitro. We also observed an enhancement of primary tumor growth in vivo. With
the exception of increased Transwell migration (not shown) however, FCM from
old fibroblasts, did not show any differences compared to FCM from young
fibroblasts (Table 3).
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Our observation that FCM promoted cell scattering and spreading, and a
spindle-shape phenotype in three of four cell types suggested the breakdown of
intercellular junctions and epithelial-mesenchymal transition (EMT). However,
Table 3. Effect of FCM from Old vs. Young PLF
on:
Morphology
Proliferation
Transwell Migration
Colony Formation
Scratch Migration
Apoptosis Resistance

LLC
No Change
No Change
Increased
No Change
No Change
No Change

except for increased vimentin, fibronectin and alpha smooth muscle actin levels in
H1792 cells, little to no changes were observed in A549, H460 and LLC cells.
These data suggest that EMT, as it is classically defined, was not responsible for
the observed changes in morphology. Interestingly, at least one group has shown
that the behavioral and morphological changes that accompany EMT are not
necessarily linked. For example, cadherin switching is necessary for increased
motility, but not the morphological changes that accompany EMT [146].
FCM affected several other processes and, as presented in Table 1, we
observed differential effects of FCM on A549, H1792, H460 and LLC cells in
several functional assays. For example, FCM stimulated Transwell migration in all
cell lines tested, but this effect was much greater in H1792 cells. FCM increased
migration across a wound in all cell lines, except H460 cells. Interestingly, colony
formation was increased in A549 cells in response to FCM, but was unchanged in
H1792 and H460 cells, and a decrease was observed in LLC cells. Lastly, FCM
could protect all cell lines from cisplatin-induced death. This was accompanied by
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a decrease in the activity of caspases 3 and 7 in A549, H1792 and LLC cells, but
not in H460 cells. There is precedent for human lung cancer cell lines behaving
differently when studied in the laboratory. For example, Liang et al, demonstrated
a decrease in cell proliferation in A549 cells, compared to a stimulation of cell
proliferation in SK-MES-1 cells, when exposed to Budesonide, a PPARa and
glucocorticoid receptor agonist. This differential effect was attributed to a mutation
in TP53 in SK-MES-1 cells [147]. Additionally, Ling et al, showed that
overexpression of MTSS1 enhanced the invasion and proliferation abilities of H920
and H1581 cells, while it inhibited invasion and proliferation in SW900 cells. These
differential effects were shown to be due to differences in FAK phosphorylation and
activity [148]. Our observations that FCM displayed differential effects depending
on what cell line was used, could explain differences observed in the literature
when comparing normal fibroblasts to carcinoma-associated fibroblasts. According
to the Cancer Cell Line Encyclopedia (CCLE) [149,150], a collaboration between
the Broad Institute, and the Novartis Institutes for Biomedical Research and its
Genomics Institute of the Novartis Research Foundation, the A549, H1792, and
H460 cell lines used in these studies have hundreds of mutations (785, 396, and
514, respectively). A search of the CCLE for common mutations known to NSCLC
revealed interesting findings. The KRAS gene was the only gene mutated in all 3
cell lines. A mutation in the p53 gene was only observed in H1792 cells. STK11
was mutated in A549 and H460 cells, while STK10 was mutated in H1792 cells.
CDKN2A is also mutated in A549 cells and H460 cells, but not H1792 cells. Lastly,
there are no known mutations in the EGFR or ALK genes. The differential effects
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in response to FCM could indeed be due to these differences in the genetic profile
of the cell lines used. Further research is needed in this area.
The observation that FCM protected both human cell lines and LLC cells
from cisplatin-induced apoptosis through effects on caspase activity is quite
intriguing as it suggests that host fibroblast-derived soluble factors, and not only
physical interaction, may influence the impact of chemotherapy on tumors.
Cisplatin is a recognized cornerstone in the treatment of lung cancer.
Unfortunately, some tumors are unresponsive, or more quickly become resistant.
To date, there are no agents in the clinic that circumvent this problem. Cisplatin
acts largely by promoting the formation of DNA adducts, mainly intrastrand
crosslinks, as well as inducing oxidative stress [151,152]. This triggers TP53 and
MAPK signaling, among others, resulting in the induction of apoptosis. Thus, one
must assume that the protective effects of FCM are due to inhibition of drug activity,
drug uptake, or over expression of anti-apoptotic signals (e.g., bcl-2). Interestingly,
our observations that FCM protected lung cancer cells from cisplatin-induced
death is not in agreement with Bartling et al, who showed that conditioned media
from WI38 fibroblasts could protect H358 cells from apoptosis induced by
paclitaxel, but not by cisplatin. [153] Our data indicate that one possible approach
to circumventing cisplatin resistance in the clinic would be to simultaneously target
fibroblast signaling in the tumor stroma during chemotherapy. At least one group
has shown that cisplatin resistance could be abrogated by inhibiting mTOR
signaling [154].
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Of all the effects of FCM, stimulation of proliferation was the most consistent
in all cell lines, and interestingly, this effect was not diminished by blocking cMET
(Table 2). This is intriguing because aberrant HGF/cMET signaling has been
shown to promote an oncogenic phenotype in various tumor types, including lung
cancers [155]. Moreover, boiling the media, blocking FGFR, and blocking the PI3K
and ERK pathways also had no effect (not shown). While this proliferative effect of
FCM was not observed in vivo, co-injection of fibroblasts and tumor cells together
increased primary tumor growth. This is likely due to the fact that the effects of
FCM are lost quickly in vivo, while fibroblasts co-injected with LLC cells persist and
thus their effects are long lasting.
The activity of FCM was impressive in certain assays, but was limited in its
influence in vivo in our models. Nevertheless, identifying the agent(s) present in
FCM responsible for these effects might unveil potential targets for intervention
that could be used in the clinic. We found that FCM was characterized by altering
cancer cell morphology and stimulating proliferation, migration, and colony
formation of several NSCLC lines, as well as protecting against cisplatin-induced
apoptosis in vitro. We also observed an enhancement of primary tumor growth in
vivo, in immunocompetent animals. Many of these effects, but importantly, not all,
were due to HGF.
Altogether, these observations suggest that FCM contains not one but
several factors capable of influencing tumor cell behavior. Our data showing
differential effects of FCM, depending on the cell type, also indicate that the role
that fibroblasts play in lung cancer progression is not as simple as a one approach
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fixes all, but is rather complex. Thus, our data suggest that targeting the tumor
stroma alone, or in combination with chemotherapy, is a promising concept that
warrants further study.
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CHAPTER IV

THE ROLE OF REDOX AND SEX IN LUNG CANCER

4.1 Introduction
Oxidative stress, classically defined as an imbalance between antioxidants
and pro-oxidants, has been implicated in a number of physiological and clinical
disorders ranging from aging and cardiovascular disease to pulmonary diseases,
diabetes,

and

cancer

[156–159].

However,

unfortunately,

large-scale

interventional studies designed to shift the balance of antioxidants and prooxidants in favor of the former have failed to show significant benefits in health
outcomes of several diseases [80–83]. As mentioned in the introduction to this
dissertation, it was suggested that the reason for the failure of these antioxidant
trials has been a misunderstanding of what oxidative stress actually is. Thus,
attention towards newer and better antioxidants may not yield better results until a
new definition of oxidative stress is considered, and treatment accordingly. Dean
Jones at Emory University has proposed a new definition as “a disruption of redox
signaling and control” [84], and has developed a way of quantifying oxidative stress
as the measurement in plasma of the redox potential (Eh) for the thiol disulfide
couples cysteine (Cys) and its oxidized form cystine (CySS), termed Eh Cys/CySS.
This is minimally invasive and represents a measure of global redox state. Eh
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Cys/CySS has been measured in humans as well as in rats, but knowledge about
the factors that influence Eh Cys/CySS in murine models is very limited, and
studies in this area have used different animal models and diverse measures of
oxidative stress. Taken together, these justify the use of animal models to test the
impact of oxidant stress and various interventions on disease development. To
gain insight into this area, we examined the effects of age, sex, fasting, and diets
on the plasma Eh Cys/CySS of C57BL6 mice and what role alterations in the Eh
Cys/CySS have in lung cancer progression in the LLC model of lung cancer. These
studies should redirect our efforts to identify key alterations in redox signaling in
oxidative stress-related diseases that will then hopefully lead to new targets for
treatment.

4.2 Materials and Methods
4.2.1 Reagents
All reagents were purchased from Sigma Chemicals (St. Louis, MO) or
Fisher Scientific (Pittsburgh, PA) unless otherwise noted.

4.2.2 Cell Culture
Lewis Lung Carcinoma (LLC; CRL-1642) cells were purchased from ATCC
(Rockville, MD) and grown in DMEM supplemented with 10% FBS, at 37 ºC in a
humidified 5% CO2 incubator. The percentage of CO2 was periodically checked
and recalibrated to maintain 5%. Cells were used within 3 months of resuscitation.
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4.2.3 Plasma Redox Potential Measurements
Blood was isolated retro-orbitally under isoflurane anesthesia, using
heparinized micro-hematocrit capillary tubes and immediately transferred to a 1.5
mL centrifuge tube containing 20 µL of L-serine, heparin, bathophenanthroline
disulfonic acid, sodium iodoacetate, and γ-glutamyl glutamate (internal standard),
and spun at 16,000 ×g for 1 minute. 100 µL of supernatant were transferred to a
new centrifuge tube containing 100 µL boric acid and perchloric acid. Samples
were mixed and frozen at -80 ºC until further use (typically 24 hours). For analysis,
samples were thawed centrifuged at 16,000 ×g for 1 minute to remove precipitated
proteins. 150 µL of supernatant were then added to 30 µL of iodoacetic acid in a
new 1.5 mL Eppendorf tube and vortexed. The pH was then adjusted to 9.0 +/- 0.2
using 1M KOH in KBO4. Afterwards, samples were incubated at room temperature
for 20 minutes after which time, 150 µL dansyl chloride was added and samples
vortexed and incubated 24 hours at room temperature in the dark. Lastly, 250 µL
CHCI3 were added and samples vortexed and analyzed by HPLC (Waters
Corporation, Millford, MA) to determine molar concentrations of cysteine, cystine,
glutathione, and glutathione disulfide, which were then used in the Nernst equation
to determine the plasma redox potential.

4.2.4 Animal Studies
All experiments were approved by the Institutional Animal Care and Use
Committee of the University of Louisville. LLC cells were plated out 24 hours prior
to injections and were harvested at ~50% confluence to ensure cells were in
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growth phase. LLC cells (1E6 /100 μl sterile PBS) were injected subcutaneously
into the hind flank of wildtype C57BL/6 mice under isoflurane anesthesia.
Afterwards, tumors were monitored and measured weekly. A tumor size >15 mm
in any direction was considered the endpoint, per IACUC regulations. Animals
were then sacrificed and tissues were harvested for analysis.

4.2.5 Sulfur Amino Acid Diets
Diets were custom-prepared by Harlan-Teklad and were designed to be
isonitrogenous. The study was designed to evaluate the response of female mice
to a diet deficient in sulfur amino acids (SAA deficient) or to a diet with excess SAA
(SAA excess). The effect of these was compared to those of an SAA control diet.
The deficient diet contained no cystine, and a reduced amount of methionine, while
the excess diet contained 3x the amount of cystine and 1.8x the amount
methionine compared to the SAA control diet. A fourth group of mice was fed a
standard chow diet. Female mice, aged 3 months old were randomly divided into
4 groups (n=10 each), and were given the following diets for 6 months: chow, SAA
control, SAA deficient, SAA excess.

4.2.6 Tissue Processing and Histological Analysis
Animals were sacrificed by CO2 administration in a closed chamber. Lungs
were flushed with PBS, inflated at standard pressure with formalin, removed, and
formalin-fixed for 48 hours. Lungs were then processed through increasing ethanol
solutions in an STP 120 Spin Tissue Processor (ThermoFisher Scientific,
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Waltham, MA), paraffin-embedded, and sectioned (6 μm) using a JUNG RM2055
microtome (Leica, Buffalo Groce, IL). Lung sections were then transferred onto
charged, glass Colorfrost microslides (VWR Sciences, Radnor, PA) for histological
analysis. Sections were deparaffinized, rehydrated, and stained with hematoxylin
and eosin (HE) to evaluate lung tumors.

4.3 Results
4.3.1 Plasma Eh Cys/CySS is Unchanged in Aged Mice but Females are
More Oxidized Compared to Males
Previous publications have demonstrated an oxidation of the plasma Eh
Cys/CySS and Eh GSH/GSSG in aged humans [78]. To determine if this occurs in
mice, plasma from young (3 months) and old (24 months) male and female mice
was isolated and analyzed by HPLC for molar concentrations of Cys, CySS, GSH,
and GSSG. We observed that aging did not impact the Eh Cys/CySS or the Eh
GSH/GSSG in male or female mice tested at 3 vs. 24 months of age (Fig. 21AB). However, interestingly, females were more oxidized when compared to males
(Fig. 22). This was mainly due to differences in Cys concentration but not to total
Cys intake. The levels of glutathione (GSH) and glutathione disulfide (GSSG) were
also unchanged with regard to aging and sex.
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Figure 21. Plasma Eh Cys/CySS and Eh GSH/GSSG are Unchanged in Old
Mice
Blood was isolated retro-orbitally from young (3 months) and old (24 months)
male and female WT C57BL/6 mice (n=8 in each group) under anesthesia, using
heparinized micro-hematocrit capillary tubes and immediately prepared for
analysis by HPLC. Plasma Eh Cys/CySS values were: young female = -91.7 +/4.9 mV; old female = -95.4 +/- 7.4 mV; young male = -108.6 +/- 9.4 mV; old male
= -104.3 +/- 3.9 mV. Plasma Eh GSH/GSSG values were: young female = -156.7
+/- 6.6 mV; old female = -152.7 +/- 4.8 mV; young male = 166.4 +/- 7.4 mV; old
male = -159.5 +/- 8.3 mV.
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Figure 22. Female Plasma Eh Cys/CySS is More Oxidized Compared to Males
Blood was isolated retro-orbitally from male (n=10) and female (n=9) WT C57BL/6
mice (3 months), under anesthesia, using heparinized micro-hematocrit capillary
tubes and processed as described in Figure 1. Plasma Eh Cys/CySS values were:
male = -108.6 +/- 5.0 mV; female = -95.2 +/- 5.7 mV; Cys values were: male = 34.3
+/- 5.9 µM; female = 21.5 +/- 3.8 µM. ***P<.001
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4.3.2 Female Mice are More Susceptible to LLC Lung Cancer Metastasis
Since female mice were found to be more oxidized in their Eh Cys/CySS,
and data in the literature suggests females are at an increased risk of lung cancer,
we speculated they may be more susceptible to lung cancer metastasis in the LLC
model. A retrospective analysis of LLC lung cancer studies in our laboratory
indicated that female mice may indeed be more susceptible to lung cancer
metastasis compared to males (data not shown). To test this prospectively, adult
(11-12 months) male and female mice were injected subcutaneously with LLC cells
and followed for tumor development. Paradoxically, tumor volume at the site of
injection was smaller for female mice (Fig. 23B), while metastasis to the lung was
markedly increased (Fig. 23B).
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Figure 23. Female Mice are More Susceptible to LLC Lung Cancer Metastasis
1E6 LLC cells were injected subcutaneously into the hindflank of WT male (11
months, n=6) and female (12 months, n=10) C57BL/6 mice. Per IACUC regulations
of endpoints, tumor formation and size were followed until a tumor size of ≥15mm
in length or width was established. All mice were then sacrificed (day 18) and lungs
harvested and processed for examination of metastases. Female mice developed
significantly more metastases to the lung compared to male mice. ***P<.001
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4.3.3 Sulfur Amino Acid Diets and Fasting Affect Plasma Eh Cys/CySS
The observation that female mice had a more oxidized Eh Cys/CySS
compared to males and were more susceptible to lung cancer metastasis in the
LLC model, led us to examine whether the two were related. To test this, we first
needed to determine if we could manipulate the Eh Cys/CySS in female mice.
Thus, female mice were placed on diets with different concentrations of sulfur
amino acids, designed to oxidize or reduce their plasm Eh Cys/CySS. Mice were
placed on the diets at 3 months of age. After 6 months, plasma was harvested and
processed for HPLC analysis. A diet containing excess sulfur amino acids was
able to significantly reduce the plasma Eh Cys/CySS (-93.6 +/- 10.0 vs.-103.4 +/9.0
mV, P = .03), while a diet deficient in sulfur amino acids was unable to significantly
oxidize the mice when compared to the SAA control diet (-93.6 +/- 10.0 vs.-86.3
+/6.8 mV, P = .07) (Fig. 24). There have been reports in the literature of a diurnal
pattern of variation of plasma redox potential that correlated with meal intake [160].
To determine if this occurred in mice, blood was drawn from young male and
female mice before and after a 24 hour fast. Interestingly, fasting did not affect Eh
Cys/CySS in females, but resulted in oxidation of the males to levels similar to
those of females (Eh Cys/CySS -96.2 mV vs. -98.8 mV) (Fig 25A). This oxidation
was caused by a decrease in the plasma levels of Cys due to fasting (34.3 +/- 5.9
vs. 23.2 +/- 2.8 µM, P<.001) (Fig. 25B).

90

Eh Cys/CySS (mV)

A

Chow

SAA Control

Concentration (µM)

SAA Excess

-20
-40
-60
-80
-100
P=.07

-120

B

SAA Deficient

0

P=.03
P<.001

250

*

200
150
*

100
50
0

*

CySS
Chow

*

Cys
SAA Control

CySSG

Total Cys

SAA Deficient

SAA Excess

Figure 24. Diets Containing Excess Sulfur Amino Acids Reduce the Plasma
Eh Cys/CySS
Female WT C57BL/6 mice (3 months; n=10 in each group) were fed a standard
chow diet, or diets with differing amounts of sulfur amino acids for 6 months. Blood
was then isolated and processed as described in the methods section. (A) Plasma
Eh Cys/CySS values were: chow = -91.7 +/- 3.0 mV; SAA control = -93.6 +/- 10.0
mV; SAA deficient = -86.3 +/- 6.8 mV; SAA excess = -103.4 +/- 9.0 mV; (B) Cys
values were: chow = 19.3 +/- 2.4 µM; SAA control = 20.3 +/- 6.2 µM; SAA deficient
= 15.3 +/- 2.9 µM; SAA excess = 33.7 +/- 13.4 µM.
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Figure 25. Fasting Alters Plasma Eh Cys/CySS in Male Mice but Not Female
Mice
Blood was isolated retro-orbitally from male (n=10) and female (n=9) WT C57BL/6
mice (3 months), under anesthesia, using heparinized micro-hematocrit capillary
tubes and processed as described in Figure 1. Mice were allowed to recover for
one week and were then fasted for 24 hours. Blood was again drawn and
processed in the same manner. (A) Unfasted plasma Eh Cys/CySS values were:
male = -108.6 +/- 5.0 mV; female = -95.2 +/- 5.7 mV. Fasted values were: male =
-98.8 +/- 3.8 mV; female = -96.2 +/- 5.0 mV. (B) Unfasted Cys values were: male
= 34.3 +/- 5.9 µM; female = 21.5 +/- 3.8 µM. Fasted Cys values were: male = 23.2
+/- 2.7 µM; female = 21.8 +/- 5.9 µM. * = significant difference between unfasted
males and females. ** = significant difference due to fasting.
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4.3.4 Alterations in Plasma Eh Cys/CySS Have No Effect on LLC Lung Cancer
Progression
Having characterized the effects of the SAA diets in mice, we set out to
determine if oxidation of the plasma Eh Cys/CySS in female mice was the cause
of their increased susceptibility to lung cancer metastasis. To test this, we injected
LLC cells into adult female mice on the aforementioned SAA diets. As depicted in
Fig. 26, oxidation of the Eh Cys/CySS had no effect on the percentage of animals
that developed lung metastases (A), or the number of metastases in the lung (B).
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Figure 26. Alterations in Plasma Eh Cys/CySS Have No Effect on LLC Lung
Cancer Progression
Mice on SAA diets (described in Figure 4) were injected 1E6 LLC cells at 9 months
of age subcutaneously into the hindflank and followed for tumor size. Once tumors
reached a size of 15mm in any direction, all mice sacrificed, and lungs harvested
and processed for examination of metastases. No differences were observed in
the percentage of mice in each group that developed tumors (A), nor were
differences observed in the number of metastases in the lungs of animals in each
group (B).
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4.4 Discussion
Oxidative stress occurs with aging and is associated with multiple agerelated diseases, such as type-2 diabetes and cardiovascular disease. Noninvasive methods to quantify oxidative stress have been lacking until recently.
Moreover, a misunderstanding of oxidative stress and treatment accordingly, has
led to the dismal failure of clinical trials in several large-scale interventional studies.
Cysteine and its disulfide form cystine, form the major low molecular weight
thiol/disulfide pair in extracellular fluids. Emerging evidence has shown that the
balance between cysteine and cystine, measured as their redox potential (Eh
Cys/CySS), can be a marker of oxidative stress and thus an important health
determinant. Dean Jones has shown that in young, healthy individuals, the Eh
Cys/CySS is around -80 mV [161] and that this value becomes more oxidized with
age [78], smoking [162] and disease, such as cardiovascular disease [79]. Taken
together, these data warrant the need for the development of murine models in
order to study oxidative stress further, as well as means of intervention. We thus
set out to study oxidative stress in a murine model, and what role this had in lung
cancer progression in the LLC model. Several observations were made as
summarized below.
First, no changes were observed in either the Eh Cys/CySS or the Eh
GSH/GSSG with regard to aging in male or female mice. This is interesting
because the progressive oxidation of Eh Cys/CySS and the Eh GSH/GSSG in
humans has been shown to occur with aging, at a pace of 0.7 mV per year after
age 45 for the Eh GSH/GSSG, and 0.2 mV a year from age 18 onward for the Eh
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Cys/CySS [78], [163]. Eh Cys/CySS values in our studies ranged from -91.7 +/4.9 mV to -108.6 +/- 9.4 mV which is consistent with the range reported for mouse
plasma [164], but more reduced compared to human plasma [78]. Likewise, values
for the Eh GSH/GSSG ranged from -152.7 +/- 4.8 mV to 166.4 +/- 7.4 mV, again,
slightly more reduced compared to human plasma. The difference of ~50 mV
between these thiol/disulfide couples indicate that they are not in equilibrium, and
thus the classical definition of oxidative stress as simply an imbalance between
pro-oxidants and anti-oxidants, is simple unacceptable. These data are important
and suggest that murine models may not be acceptable models to study the
progressive oxidation of thiol-disulfide couples that occur with aging. Although we
observed no effect with aging, we did observe that female mice were oxidized in
their Eh Cys/CySS, but not in their Eh GSH/GSSG when compared to males,
regardless of age. Studies in humans have showed no differences in regard to sex,
but these studies were not designed specifically to examine the role of sex, and
are therefore not conclusive. The reasons for these differences in female mice
remain unexplained.
Second, we observed that while female mice developed smaller tumors at
the site of injection, they were more susceptible to lung cancer metastasis in the
LLC subcutaneous model of lung cancer. It has been reported in humans that
females typically have smaller tumors [165]. There are also numerous studies in
the literature detailing an increased risk of lung cancer in humans in both smokers
and particularly in never-smokers [99,166–170]. Several mechanisms have been
proposed, but of particular interest is the role of estrogens, which have been
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proposed to lead to increased amounts of oxidative DNA damage [171,172].
Smoking has been shown to increase the levels of CYP1B1, which is expressed
in the lung. CYP1B1 then metabolizes estrone (E1) and 17b-estradiol (E2) into the
catechol estrogens, 4-OHE1 and 4-OHE2, respectively. These catechol estrogens
then lead to DNA damage [173,174]. It is important to note that others are not in
agreement with the notion that females are more susceptible to lung cancer
[175,176].
Third, we showed that we were able to significantly reduce the Eh
Cys/CySS in female mice using diets that were deficient in certain sulfur amino
acids. We were, however, unable to significantly oxidize these same animals by
using diets with excess amounts of sulfur amino acids. This has been evaluated in
rats, where a diet deficient in SAA was shown to significantly oxidize the Eh
Cys/CySS, and diet with excess SAA was able to significantly reduce the Eh
Cys/CySS [177]. It has been shown that oxidative stress is reduced in those
consuming a Mediterranean diet [178]. There is also evidence showing that tissue
levels of GSH can be affected by dietary inducers [179]. Thus, there is a need to
understand the dietary factors that affect Eh Cys/CySS and Eh GSH/GSSG. The
data presented here are important in that they allow for interventional studies in a
murine model, which will possibly help shed light on what occurs in humans [180].
Lastly, the increased susceptibility of female mice to lung cancer metastasis
does not appear to be due to the fact that they are more oxidized in their Eh
Cys/CySS. The canonical view of oxidative stress in terms of cancer is that ROS
contribute to malignant progression of tumors by promoting, among others,
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genomic instability. Indeed, oxidative stress has been shown to promote cancer
progression in several studies, evidenced by the use of antioxidants. For example,
Gao et al., reported anti-tumorigenic effects of N-acetyl cysteine (NAC) and vitamin
C in multiple tumorigenic murine models. It was shown that this effect was not only
due to decreased levels of DNA damage, but also to decreased levels of HIF [181].
NAC was also shown to slow tumor progression in p53-dependent mouse model
of lymphomagenesis [182]. However, paradoxically, others have shown that
oxidative stress can inhibit cancer metastasis. Wu et al., showed that the ability of
isothiocyanates to decrease the metastatic potential of NSCLC lines was due to
their induction of oxidative stress [183]. Additionally, Piskounova et al., reported
that anti-oxidants promoted distant metastasis of melanoma cells in NSG mice,
while having no effect on the growth of the primary tumor [184]. These latter
observations, among others, have posited some to describe metastasis as an
escape from oxidative stress [185]. Our studies involving SAA diets were unique,
in that they could test whether or not oxidative stress could inhibit or promote
metastasis. If oxidation of the Eh Cys/CySS was important in LLC lung cancer
progression, the biggest difference would be observed between SAA excess and
SAA deficient diet groups. However, we observed no differences in lung cancer
metastasis between these groups. It could be argued that one of the reasons we
failed to see differences is due to a small mV change due to the diets (10-15mV).
However, a 15 mV change in redox potential, will cause a 5-fold change in a dithiol/
disulfide motif [186]. Another explanation may be related to the short time frame
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of the studies, which cannot possibly mimic the human conditions where exposure
to pro-oncogenic factors may last years.
Taken together, this work extends our understanding of redox changes with
regard to aging and fasting, 2 major life processes. It was surprising that while a
24 hour fast was able to significantly oxidize male mice, aging had no effect on
redox state in either sex. Interestingly, this same phenomenon has been observed
in Drosophila melanogaster [187]. These data suggest that redox processes are
more complicated than previously suspected and warrant additional research.
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CHAPTER V

SUMMARY AND DISCUSSION

5.1 Restatement of Goals
Lung cancer occurs almost exclusively in elderly individuals. In fact, only 35% of lung cancers occur in individuals under the age of 40. Aging is characterized
by multiple abnormalities, such as increased oxidative stress, chronic
inflammation, decreased immune function, and alterations in tissue ECM. Lung
cancer also commonly occurs in those with pre-existing pulmonary diseases such
as COPD and IPF (also increased in the elderly), which are marked by lung
inflammation and tissue remodeling. Although the majority of lung cancers occur
in former or active smokers, only 20% of lifetime smokers will acquire lung cancer.
Moreover, data in the literature using old animals to study lung cancer are scarce,
contradictory, and usually evaluated only primary tumor growth at the site of
injection [188]. For this reason, we set out to explore what host factors in the elderly
are responsible for the increased susceptibility to lung cancer, by testing the
following hypothesis: while smoking and other environmental exposures can lead
to lung cancer development in a genetically susceptible individual, increased
oxidation of the Eh Cys/CySS in the aging lung creates an oncogenic
microenvironment, specifically by increased fibronectin EDA levels, that renders
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the host susceptible to lung cancer progression (Figure 1). Several observations
were made as summarized below.

5.2 Main Findings of This Dissertation
Through both subcutaneous and intravenous injection of LLC cells, we
showed that aged C57Bl/6 mice were more susceptible to lung cancer progression,
marked by increased metastases to the lung in the subcutaneous model, and an
increased number of tumors in the lung in the intravenous model. This effect of
aging is in agreement with those of Gozez and Trainin who showed tumor
incidence and growth rate of the primary tumor was increased in direct proportion
to age in C57Bl/6 mice injected subcutaneously with LLC cells (metastasis was not
evaluated) [189]. Yuhas and Ulrich also showed an increase in lung tumors with
aging using Line 1 cells [190]. In contrast, Ershler found decreased survival and
increased metastasis in younger animals using LLC cells and B16 melanoma cells
[191]. Lastly, Anisimov and Zhukovskaya, using LLC cells, showed no effect of age
on the growth of the primary tumor or survival (metastasis was not evaluated).
[192]. These contradictory reports suggest differences in animal models and
methodology, while emphasizing the need for further research in this area.
Interestingly, one of the proposed causes of these discrepancies has been the sex
of mice used, as many of the earlier studies did not indicate what sex was tested.
In this dissertation, we have outlined that female mice are indeed more susceptible
to lung cancer metastasis in the LLC model when compared to males, and develop
larger tumors at the site of injection. Our data clearly showed that aging renders
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the host susceptible to lung cancer progression in the LLC model. This ‘aging
effect’ does not appear related to tumor implantation, growth, or metastasis from
the primary tumor, and the effects of immunity appear limited. Instead, the aging
effect appears to be ‘lung dependent’. Our lab has previously shown that the aged
murine lung is characterized by a pro-fibrotic phenotype. Considering this, we
hypothesized that the aging effect related to the extracellular matrix deposited in
the microenvironment. To test this, we engaged in studies using fibronectin EDA
KO mice. However, we showed that fibronectin EDA was not important for lung
cancer progression in uninjured lungs.
Fibronectin EDA is increased in the aged lung and has been shown to be a
vascular marker for solid tumors and metastases. Moreover, immunization against
fibronectin EDA decreases tumor burden and lung metastases in the MMTV-PyMT
transgenic model of metastatic mammary carcinoma. This and other observations
justify testing fibronectin EDA. Nevertheless, we observed no differences in
primary tumor growth, or metastases to the lung in the LLC model when using
fibronectin EDA KO mice. As mentioned in the Future Studies section, studies are
ongoing using KRAS mice to determine if EDA has a role in lung cancer
development.
Third, by using the bleomycin model of pulmonary fibrosis, followed by
injection of LLC cells, we showed that lung inflammation/tissue remodeling
increased metastases to the lung, but only in aged mice, and not young mice. Due
to reports that fibronectin EDA KO mice were protected from bleomycin-induced
pulmonary fibrosis, we chose to use these animals to begin to determine the
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mechanisms increased tissue remodeling in the lung played in LLC lung cancer
progression. In our hands, fibronectin EDA KO mice were found to develop the
same degree of pulmonary fibrosis as WT mice. We repeated these experiments
several times in both male and female mice. Surprisingly, despite the presence of
pulmonary fibrosis, bleomycin was unable to increase metastases to the lung in
fibronectin EDA KO mice, suggesting that EDA plays a crucial role for lung cancer
progression in the setting of aging and lung injury. In WT animals treated with
bleomycin, we observed that ~90% of metastases to the lung occurred in areas of
fibrosis. This was not observed in fibronectin EDA KO mice, which suggests that
EDA acts a scaffold for the recruitment and organization of tumor cells in the lung.
This is consistent with our observation that most metastatic lesions co-localized
with areas of tissue remodeling. Additionally, in vitro, we observed that fibronectin
EDA increased proliferation and migration of LLC cells.
Fourth, we found that immunity played an important role in age-related
susceptibility to lung cancer progression in the LLC model. The differences in
young vs. old WT mice were abolished in NSG mice. Young NSG mice developed
metastases to the lung while young WT animals did not, suggesting that young WT
animals are able to successfully mount a defense against lung cancer progression.
While the number of metastases to the lung in aged NSG mice was still greater
than those in young NSG mice, this was not statistically significant. However,
importantly, the size of the lung tumors in the aged NSG mice were significantly
larger than those observed in young NSG mice. These data support our hypothesis
that the microenvironment of the aged lung (specifically alterations in ECM
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proteins) itself renders the host susceptible to lung cancer progression. The cause
of the differences in location of lung metastases in WT vs. NSG mice remain
unexplained.
Fifth, we observed no changes in the oxidation of either the Eh Cys/CySS
or the Eh GSH/GSSG with aging in mice. Oxidation of these thiol/disulfide couples
has been shown to occur in humans, and our lab has previously reported that
oxidation of the Eh Cys/CySS in lung fibroblasts alters matrix gene expression,
specifically, increased expression of fibronectin and the growth factor TGFb. For
these reasons, we hypothesized that the increased susceptibility of old mice to
lung cancer progression was due to oxidation of the Eh Cys/CySS, which led to
altered matrix composition in the old lung. While this was not found to be the case,
we observed that female mice were more oxidized in their Eh Cys/CySS, but not
in their Eh GSH/GSSG, when compared to males. We also observed that female
mice were more susceptible to lung metastases in the LLC model. To determine if
these were related, we engaged in studies using SAA diets. We were able to
significantly reduce the Eh Cys/CySS in females to levels observed in males.
However, this had no effect on lung metastasis to lung, suggesting that oxidation
of thiol/disulfide couples has no role in aging or lung cancer progression in mice.
We suspect that the time frame of the experiments prevented us from observing a
differential effect. Our studies were performed within weeks of the intervention,
while humans are likely oxidized for years prior to the latter promoting alterations
in ECM composition and having a pro-oncogenic effect. Either way, it remains to
be determined why aged, female WT mice are more susceptible to lung cancer
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progression in the LLC model. Interestingly, females were found to have increased
levels of fibronectin EDA in whole lung homogenates (Fig. 27).
Lastly, we showed that normal, untransformed lung fibroblasts play an
important role in lung cancer progression. Fibroblasts are the predominant cell type
in the tissue stroma and are the main source of ECM proteins. As such, they play
prominent roles in tissue remodeling and thus pulmonary fibrosis. Our lab has also
shown that old fibroblasts have defects in control of their redox state. This was
found to be due to a 10-fold decreased expression of the Slc7a11 subunit of the
xCT cystine-glutamate transporter in primary lung fibroblasts harvested from 24month old mice. For this reason, we engaged in studies evaluating the role that
young and old fibroblasts played in lung cancer progression. Based on the vast
number of reports in the literature studying cancer-associated fibroblasts (albeit
few in the lung), we hypothesized that ‘normal’ young fibroblasts would play little
to no role in lung cancer progression and that old fibroblasts would. Surprisingly,
FCM from normal young fibroblasts was found to alter the morphology of several
lung cancer cell lines, as well as increase their proliferation, confer resistance to
cisplatin, increase colony formation, increase Transwell migration, and increase
wound healing. Little differences were observed between the effect of FCM from
young and old fibroblasts. Despite large differences observed in vitro in response
to FCM, we observed no differences in vivo in metastases to the lung or growth of
the primary tumor. We did, however, observe larger tumors at the site of injection
when LLC cells were co-injected with PLF.
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Figure 27. FNA EDA Protein Levels in Female and Male Whole Lung
Homogenates
Protein was isolated from female (n=4) and male (n=4) murine whole lung
homogenates followed by Western Blot analysis for FN EDA (Abcam, ab6328;
1:400) and GAPDH (Sigma, G9545; 1:10,000). Blots were scanned on a LI-COR
Odyssey CLx imaging system and analyzed in Image Studio (LI-COR).
Quantification was performed using ImageStudioLite software. *P < .05
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Fewer people are dying today from lung cancer than ever before, a fact to
be celebrated, but one that is due largely to a decreased incidence of lung cancer
due to fewer smokers, rather than better treatment and early detection strategies.
The dismal five-year survival rate for lung cancer remains below 20% and over one
million people will still die worldwide from lung cancer every year. While the number
of lung cancers due to tobacco use is declining, smoking rates remain over 30%
for most countries worldwide, and the use of e-cigs is increasing each year at an
alarming pace. While the vast majority of lung cancers occur in those who have
histories of, or who currently are, smoking, only 20% of smokers will acquire lung
cancer. There are also a large number of individuals who develop lung cancer who
have never smoked a day in their lives. These data suggest that other factors are
also important in predisposing individuals to the development of lung cancer. This
observation formed the basis for this work. The data presented in this dissertation
can be summarized by the following: age-dependent host factors, including
immunity and fibroblast-derived factors, influence lung cancer progression.
Importantly, lung inflammation/tissue remodeling augments pulmonary metastasis
in the aging lung, but not in young lungs, through mechanisms involving fibronectin
EDA, which perhaps provides a scaffold for tumor cell proliferation, organization,
and migration. These events seem to be amplified in females, suggesting a role
for sex. We could find no role for redox oxidation in lung cancer progression. These
data point to an interplay between lung aging and inflammation/remodeling in lung
tumor progression. This dissertation underscores the need for further studies in
the role of the host to unveil new anti-lung cancer therapies.
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5.3 Strengths and Weaknesses
Strengths
The work presented here has several strengths that have helped shed light
on how age-dependent host factors influence lung cancer progression. First, this
works unveils a previously unknown role for fibronectin EDA in lung cancer
progression. Of particular interest is that EDA only plays a role in the aged lung, in
the setting of lung injury. In our model, it did not play a role in uninjured lungs in
young or old animals.
Second, the use of multiple assays, several lung cancer and lung fibroblast
cell lines as well as primary fibroblasts, and the complementary use of in vitro and
in vivo models, allowed us to address an area for which there is no perfect model.
All models, by nature, simplify the complexity human diseases. Of particular
importance is our use of both immunocompetent and immunocompromised
animals. While xenografts in immunocompromised animals are important in being
able to study human cell lines by avoiding host rejection, they rarely metastasize
and they do not allow one to dissect the role of host immunity in tumor growth and
metastasis. This is a major drawback, as metastasis is what often kills patients.
Studies often focus on the primary tumor, which is usually resected in the clinic.
Our use of NSG mice was not to study human cell lines, but to determine what
role, if any, immunity had in observations in immunocompetent animals.
Lastly, the work presented here allowed for the careful characterization of
the murine model of lung cancer by addressing a diverse range of host factors
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ranging from age to redox to sex to tissue remodeling, many of which are observed
in humans.

Weaknesses
The work described here is by no means perfect. Science is based on
experiments and observations, both of which can be flawed, which can then lead
to flawed conclusions. Thus, it is imperative that the work be replicated and
expanded to test mechanisms of action and potential interventions.
One weakness of this work is the use of the Lewis Lung Carcinoma model
of lung cancer. While this model has been used extensively over the years, and
much is known about it, it does not completely represent lung cancer development
in the human. This is the case for all syngeneic and xenograft models. For this
reason, studies in are lab our ongoing using the KRAS model of spontaneous lung
cancer development (see future directions).
Another weakness is that, other than the studies utilizing isolated primary
lung fibroblasts, fibronectin EDA KO mice, and cMET inhibitors, there are limited
mechanistic data. This is understandable as studies characterizing the model had
to be completed first. Studies evaluating receptor function and intracellular
signaling pathways will need to be performed in the future.
Fibronectin EDA was shown to be necessary for the increased susceptibility
of the injured, aged lung to lung cancer metastasis. Admittedly, strategies for
targeting fibronectin would be limited due to the high concentration of fibronectin
in the plasma and other organs, but much work is being done in this area. Perhaps
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a better approach would be to target fibronectin recognition by blocking its
association with its various integrins [193].

5.4 Future Directions
Good science always raises more questions than it answers, and the work
presented here is no different. There are several observations that remain
unexplained in three keys areas presented in this dissertation:

5.4.1 How does aging impact cancer progression?
While we were able to show, in studies utilizing NSG mice, that immunity
played a role in the increased susceptibility to lung cancer progression in the aged
mice, there were still differences observed with aging (larger tumors in the lung),
suggesting that other factors besides immunity play a role. In addition to the role
of fibronectin EDA, it would be interesting to test which integrins mediate this effect
and what other ECMs, the various collagens, for example, influence cancer
progression.
We also plan to perform additional studies as outlined here, but with the B16
melanoma cell line. These studies will be important to determine if the effect of
aging that we observed is truly due to intrinsic factors in the host, or to intrinsic
properties specific to LLC cells.
As mentioned previously, there are limitations to using syngeneic and
xenograft models, as they do not fully recapitulate the human condition (e.g.
angiogenesis and tissue microenvironment). For this reason, we plan to perform
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additional studies using the KRAS model of spontaneous lung cancer
development. KRAS is a potent oncogene that is mutated in 30% of human NSCLC
cases [194]. This leads to a constitutively active pathway and the spontaneous
development of lung carcinomas, which more closely resembles the human
condition. By breeding fibronectin EDA mice with KRAS mice, we have developed
animals that are lacking fibronectin EDA and that also spontaneously develop
tumors. This will allow to evaluate the role of fibronectin EDA in lung cancer
development. Studies are ongoing in our lab in this area.
Lastly, one must consider the role that epigenetics plays, not only in the
aging process itself, but also in age-related disease susceptibility. Epigenetics
refers to the study of inheritable changes in gene function without alterations to the
underlying DNA sequence. This is important as it provides a target for intervention.
At present, changes to the DNA sequence in humans are irreversible. The
deterioration of cellular functions that occur with aging are characterized by
epigenetic changes, which may be due to both internal and/or external stimuli
[195]. Several epigenetic changes occur in aging including chromatin remodeling
[196,197], but one of the best characterized modifications involve alterations in
DNA methylation patterns at CpG sites in gene promoter regions, which typically
become hypomethylated (hypermethylation has been observed in certain regions
[198]) with age, and ultimately affect gene expression by preventing access of RNA
polymerase II [199]. This age-associated CpG hypomethylation is similar to global
hypomethylation observed in most cancers and may provide a potential link
between epigenetics and age-related cancer susceptibility in the elderly population
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[200]. Indeed, it was recently shown that standardized measures of intrinsic
epigenetic age acceleration (IEAA) were significantly associated with lung cancer
incidence in aged females, suggesting that IEAA might serve as a useful biomarker
for determining lung cancer susceptibility [201].

5.4.2 What is the identity of soluble factor(s) in FCM that promote lung
cancer?
We were able to identify and determine that HGF was responsible for
several, but importantly not all, of the effects of FCM we observed in vitro. We were
also able to rule out several components. Of interest were our data showing that
charcoal-stripping of the FCM was able to prevent the protection from cisplatin in
several NSCLC lines tested in vitro, although it was unable to block the mitogenic
effect of FCM. This indicates that a non-polar, possibly lipid-based molecule is
responsible for these effects. Additional work will need to be performed to discover
the identity of this molecule(s).

5.4.3 What is the role of sex in lung cancer progression?
In these studies, female mice were found to be more oxidized in their Eh
Cys/CySS and were more susceptible to lung cancer progression in the LLC
model. Our studies with the SAA diets suggested that these two were not related.
This could however be due to limitations inherent in the SAA diets or the timing of
the experiments. To investigate this further, we plan to treat female mice with
sulforaphane, an isothiocyanate compound obtained from cruciferous vegetables
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that has been shown to reduce the Eh Cys/CySS by increasing the levels of
Slc7a11, a cystine-glutamate transporter. We also plan to repeat studies with the
SAA diets in males, as we only performed studies using females.
One observation that remains unexplained is the increased oxidation of the
Eh Cys/CySS in female mice. It is unknown if this also occurs in humans, or if this
is simply a murine phenomenon. There is at least one report in the literature
detailing increased oxidative stress in female C57BL/6 mice compared to males,
as determined by electron para-magnetic resonance spectrometry and
dihydroethidium oxidation in the brain [202]. Nevertheless, the factors responsible
for this observation could explains other differences in female humans, such as an
increased incidence of COPD in never-smokers.
Lastly, we observed that aged female mice had more fibronectin EDA
protein levels in whole lung homogenates when compared to males. Whether this
plays a role in their increased susceptibility to lung cancer progression in the LLC
model remains to be seen.
Whenever the topic of sex is being investigated as a biological variable, one
must take into account the obvious: the role of sex hormones. For this, we plan to
repeat many of the studies described here, but in ovariectomized females, or
castrated males. If differences are observed, then studies will again be repeated
with hormone replacement using estradiol in females and testosterone in males.
These studies will shed light on the role that sex hormones play in lung cancer
progression and oxidative stress in males and females.
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5.4.4 Could SAA diets play a role in prevention?
While our studies using SAA diets suggested that neither oxidation of the
Eh Cys/CySS or the Eh GSH/GSSG played no role in lung cancer progression,
this could be due to limitations of the LLC model. For this reason, we plan to repeat
experiments with the SAA diets in KRAS mice, which spontaneously develop lung
tumors, to determine what role, if any, thiol/disulfide couples play in lung cancer
development. Exposure of animals to the diets for prolonged periods of time would
also help further define this observation.

5.4.5 What is the role of the lung microbiome?
An emerging and exciting area of research pertains to the role of the
microbiome (used synonymously with microbiota) in both normal and diseased
states. The microbiome refers to the abundant and diverse bacterial, fungal, viral,
and archaea populations that exist on and within the human body. In 2008, the NIH
launched the Human Microbiome Project (HMP), which was tasked with studying
how changes in the human microbiome associated with health and disease. The
microbiome indeed has been shown to play crucial roles in maintaining normal
homeostasis in the body, but has also been found to be altered in several disease
states [203]. The most extensively studied microbiome is in the gut, which has the
highest density of microorganisms in the body, with approximately 1014 bacteria
[204]. Astonishingly, it has been reported that every human is host to trillions of
bacterial cells, whose genome, in the gut, for example, contains at least 100 times
as many genes as our own genome [205]. Alterations in the microbiome of the gut
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(referred to as gut dysbiosis) are thought to be responsible for gastrointestinal
diseases such as irritable bowel syndrome (IBS), peptic ulcers, and many gastric
malignancies [206]. Of interest to this dissertation are studies indicating an effect
of gut dysbiosis on the lung, a relationship referred to as the “gut-lung axis.” For
example, individuals suffering from IBS often have impaired lung function [207]. A
strong correlation between decreased microbial diversity in infancy and the
development of asthma later in life has also been noted [208]. A variety of other
lung disorders, such as COPD and cystic fibrosis, have also been linked to
microbial dysbiosis [209–211]. In terms of cancer, a Danish population-based
cohort study found that individuals with Crohn’s disease, but not ulcerative colitis,
had an increased risk of lung cancer that was associated with female gender and
smoking [212]. While research in this area is still in its infancy, there have been
several promising studies detailing how we might take advantage of the
microbiome and its effect, for example, on immunity, in our fight to eradicate cancer
[213–215].
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LIST OF ABBREVIATIONS

aSMA

Alpha Smooth-Muscle Actin

BAL

Bronchoalveolar Lavage

BLEO

Bleomycin

CCLE

Cancer Cell Line Encyclopedia

cFN

Cellular Fibronectin

cMET

Hepatocyte Growth Factor Receptor

CAFs

Cancer-Associated Fibroblasts

CO2

Carbon Dioxide

COPD

Chronic Obstructive Pulmonary Disease

Cys

Cysteine

CySS

Cystine

DAPI

4',6-diamidino-2-phenylindole

DMEM

Dulbecco’s Modified Eagle Medium

E1

Estrone

E2

17b-Estradiol

ECAD

E-Cadherin

E-cig

Electronic Cigarette

ECM

Extracellular Matrix
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EDA

Extra Domain A

EDB

Extra Domain B

Eh

Redox Potential

EMT

Epithelial Mesenchymal Transition

ERK

Extracellular Signal–Regulated Kinase

FCM

Fibroblast Conditioned Media

FBS

Fetal Bovine Serum

FGF

Fibroblast Growth Factor

FN

Fibronectin

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GSH

Glutathione

GSSG

Glutathione Disulfide

HE

Hematoxylin and Eosin

HGF

Hepatocyte Growth Factor

HIF

Hypoxia-Inducible Factor

HMP

Human Microbiome Project

HPLC

High-Performance Liquid Chromatography

IACUC

Institutional Animal Care and Use Committee

IBS

Irritable Bowel Syndrome

IEAA

Intrinsic Epigenetic Age Acceleration

IPF

Idiopathic Pulmonary Fibrosis

IV

Intravenous Injection

KO

Knockout
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LLC

Lewis Lung Carcinoma

mTOR

Mammalian Target of Rapamycin

mV

Millivolts

NAC

N-Acetyl Cysteine

NCDs

Noncommunicable diseases

NIH

National Institutes of Health

NNK

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone

NNN

N'-nitrosonornicotine

NSCLC

Non-Small Cell Lung Cancer

NSG

NOD scid gamma

PAHs

Polycyclic Aromatic Hydrocarbons

PBS

Phosphate Buffered Saline

PBST

Phosphate Buffered Saline with Tween

pFN

Plasma Fibronectin

PI3K

Phosphatidylinositol-3-Kinases

PLF

Primary Lung Fibroblasts

RPM

Revolutions Per Minute

RNS

Reactive Nitrogen Species

ROS

Reactive Oxygen Species

SAA

Sulfur Amino Acid

SCLC

Small Cell Lung Cancer

SDS

Sodium Dodecyl Sulfate

TGFb

Transforming Growth Factor b
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TSNAs

Tobacco Specific Nitrosamines

US

United States

VIM

Vimentin

WT

Wildtype

xg

Relative Centrifugal Force
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